WO2018124181A1 - mRNAの機能化方法 - Google Patents
mRNAの機能化方法 Download PDFInfo
- Publication number
- WO2018124181A1 WO2018124181A1 PCT/JP2017/046906 JP2017046906W WO2018124181A1 WO 2018124181 A1 WO2018124181 A1 WO 2018124181A1 JP 2017046906 W JP2017046906 W JP 2017046906W WO 2018124181 A1 WO2018124181 A1 WO 2018124181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mrna
- sequence
- rna
- oligomer
- bases
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 684
- 238000000034 method Methods 0.000 title claims description 85
- 238000007306 functionalization reaction Methods 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 567
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 87
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 129
- 230000000295 complement effect Effects 0.000 claims description 126
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 99
- 229940126582 mRNA vaccine Drugs 0.000 claims description 91
- 238000012986 modification Methods 0.000 claims description 73
- 230000004048 modification Effects 0.000 claims description 73
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 108091007433 antigens Proteins 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 49
- 239000000693 micelle Substances 0.000 claims description 46
- 238000007385 chemical modification Methods 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 35
- 229920001223 polyethylene glycol Polymers 0.000 claims description 35
- 239000002671 adjuvant Substances 0.000 claims description 33
- 229920000642 polymer Polymers 0.000 claims description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 29
- 125000001165 hydrophobic group Chemical group 0.000 claims description 24
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 19
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 230000000087 stabilizing effect Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000032258 transport Effects 0.000 description 85
- 230000014509 gene expression Effects 0.000 description 74
- 238000009396 hybridization Methods 0.000 description 59
- 108010056869 poly(ethylene glycol)-poly(N'-(N-(2-aminoethyl)-2-aminoethyl)aspartamide) block copolymer Proteins 0.000 description 53
- 239000000243 solution Substances 0.000 description 49
- 238000002474 experimental method Methods 0.000 description 43
- 108020005345 3' Untranslated Regions Proteins 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 37
- 230000014616 translation Effects 0.000 description 37
- 108091026890 Coding region Proteins 0.000 description 35
- 108700026244 Open Reading Frames Proteins 0.000 description 32
- 206010061218 Inflammation Diseases 0.000 description 31
- 230000004054 inflammatory process Effects 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 28
- 238000013518 transcription Methods 0.000 description 27
- 230000035897 transcription Effects 0.000 description 27
- 108020003589 5' Untranslated Regions Proteins 0.000 description 25
- 238000013519 translation Methods 0.000 description 25
- 238000000338 in vitro Methods 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 230000001976 improved effect Effects 0.000 description 18
- 230000000692 anti-sense effect Effects 0.000 description 17
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 15
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 15
- 108020004635 Complementary DNA Proteins 0.000 description 15
- 108010058846 Ovalbumin Proteins 0.000 description 15
- 238000010804 cDNA synthesis Methods 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 229940092253 ovalbumin Drugs 0.000 description 15
- 108091036066 Three prime untranslated region Proteins 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 12
- 239000005089 Luciferase Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 229920006317 cationic polymer Polymers 0.000 description 12
- 230000007515 enzymatic degradation Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 12
- 239000012620 biological material Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004671 cell-free system Anatomy 0.000 description 11
- 230000007969 cellular immunity Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 229940022005 RNA vaccine Drugs 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 210000004748 cultured cell Anatomy 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 230000006641 stabilisation Effects 0.000 description 10
- 238000011105 stabilization Methods 0.000 description 10
- 235000011178 triphosphate Nutrition 0.000 description 10
- 239000001226 triphosphate Substances 0.000 description 10
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 108091081021 Sense strand Proteins 0.000 description 9
- 239000006227 byproduct Substances 0.000 description 9
- -1 cationic lipid Chemical class 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 8
- 238000011530 RNeasy Mini Kit Methods 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 229920001400 block copolymer Polymers 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229940023146 nucleic acid vaccine Drugs 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 108020004394 Complementary RNA Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 102000003996 Interferon-beta Human genes 0.000 description 7
- 108090000467 Interferon-beta Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000003184 complementary RNA Substances 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 229960001388 interferon-beta Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 6
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 6
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 description 6
- 235000011010 calcium phosphates Nutrition 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 229920001477 hydrophilic polymer Polymers 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 235000010981 methylcellulose Nutrition 0.000 description 6
- 239000005022 packaging material Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 108700026220 vif Genes Proteins 0.000 description 6
- 241000963438 Gaussia <copepod> Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000012124 Opti-MEM Substances 0.000 description 5
- 108010052090 Renilla Luciferases Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000004727 humoral immunity Effects 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 229920000447 polyanionic polymer Polymers 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000003633 gene expression assay Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000005965 immune activity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229920000831 ionic polymer Polymers 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 210000001995 reticulocyte Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 3
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 3
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 102000004018 Caspase 6 Human genes 0.000 description 3
- 108090000425 Caspase 6 Proteins 0.000 description 3
- 108090000567 Caspase 7 Proteins 0.000 description 3
- 102100029855 Caspase-3 Human genes 0.000 description 3
- 102100038902 Caspase-7 Human genes 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 229930185560 Pseudouridine Natural products 0.000 description 3
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940028617 conventional vaccine Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 3
- 108010011110 polyarginine Proteins 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229920000428 triblock copolymer Polymers 0.000 description 3
- 229940048102 triphosphoric acid Drugs 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 2
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102100026549 Caspase-10 Human genes 0.000 description 2
- 108090000572 Caspase-10 Proteins 0.000 description 2
- 102000004046 Caspase-2 Human genes 0.000 description 2
- 108090000552 Caspase-2 Proteins 0.000 description 2
- 102100026548 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 102100026550 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108700021154 Metallothionein 3 Proteins 0.000 description 2
- 102100028708 Metallothionein-3 Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 2
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010037075 Protozoal infections Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 238000007098 aminolysis reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000011337 individualized treatment Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 239000010954 inorganic particle Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 102000027411 intracellular receptors Human genes 0.000 description 2
- 108091008582 intracellular receptors Proteins 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 101100290713 Caenorhabditis elegans mef-2 gene Proteins 0.000 description 1
- 101000841393 Candida albicans Probable NADPH dehydrogenase Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 101710090338 Caspase-4 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 102000002664 Core Binding Factor Alpha 2 Subunit Human genes 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 101150082208 DIABLO gene Proteins 0.000 description 1
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 102100029055 Exostosin-1 Human genes 0.000 description 1
- 102100029074 Exostosin-2 Human genes 0.000 description 1
- 101150019331 FGF2 gene Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102100031561 Hamartin Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000866618 Homo sapiens 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 description 1
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000918311 Homo sapiens Exostosin-1 Proteins 0.000 description 1
- 101000918275 Homo sapiens Exostosin-2 Proteins 0.000 description 1
- 101000795643 Homo sapiens Hamartin Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000616556 Homo sapiens SH3 domain-containing protein 19 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 1
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101100007739 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) crmA gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108010085839 Neurofibromin 2 Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 102100021117 Serine protease HTRA2, mitochondrial Human genes 0.000 description 1
- 101710146118 Serine protease HTRA2, mitochondrial Proteins 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 102000049937 Smad4 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 101710173511 Tensin homolog Proteins 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100031638 Tuberin Human genes 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102000018252 Tumor Protein p73 Human genes 0.000 description 1
- 108010091356 Tumor Protein p73 Proteins 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 208000002761 neurofibromatosis 2 Diseases 0.000 description 1
- 208000022032 neurofibromatosis type 2 Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 101150000251 xiap gene Proteins 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0001—Archaeal antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method for functionalizing mRNA. More specifically, the present invention relates to a method for stabilizing an mRNA transport carrier, an mRNA vaccine, and the like.
- MRNA delivery is attracting attention as a method for safely and continuously supplying therapeutic proteins.
- methods for protecting mRNA from degradation using an mRNA transport carrier and methods for improving mRNA molecules themselves have been studied, but further innovating due to the extremely strong RNase in vivo. Is required.
- Non-Patent Document 1 a method of substituting a part of the mRNA base with a chemically modified one has been studied.
- Various chemically modified bases have been comprehensively studied so far, but no one that can greatly improve the enzyme resistance of mRNA has been reported yet.
- free chemical modification was difficult.
- Patent Document 1 describes a polycationic polymer and a polyion complex of mRNA, and describes that this is used for delivery of mRNA.
- Non-Patent Document 2 describes the stability of polymeric micelle-type mRNA transport carriers, the evaluation of enzymatic degradation, and the effect of cholesterol modification on polymers.
- these documents do not describe a method for stabilizing an mRNA transport carrier that can improve enzyme resistance of mRNA without greatly reducing the efficiency of protein translation from mRNA in vivo.
- Nucleic acid vaccines such as DNA vaccines and mRNA vaccines use nucleic acids to present antigenic proteins. That is, the nucleic acid vaccine activates immunity by transferring the administered nucleic acid into the nucleus or cytoplasm of the antigen-presenting cell to express the antigen protein and presenting the antigen protein. Nucleic acid vaccines are considered to be safer than live vaccines because there is no problem of reversion of pathogenicity. In addition, in the nucleic acid vaccine, the antigen-presenting cells present the antigen protein, so that cellular immunity can be induced. For this reason, the nucleic acid vaccine can be developed for cancer and chronic infectious diseases. Furthermore, it is possible to design a relatively free nucleic acid simply by changing the sequence of the nucleic acid vaccine. Therefore, the nucleic acid vaccine can be used for individualized treatment of cancer, and can respond quickly to viral mutations. There are also advantages such as being able to respond quickly to a pandemic.
- DNA vaccines are considered to be at risk of mutagenesis due to random insertion into the host genome.
- mRNA vaccines that use mRNA to present antigenic proteins are considered to be free from the risk of mutagenesis into the host genome and have attracted attention in recent years.
- Such a conventional mRNA vaccine has the following three problems.
- the first problem is that when a foreign substance is used as an adjuvant, considerable attention must be paid to its safety.
- the second problem is that if the administered mRNA and the tissue distribution of the adjuvant are different, a sufficient inflammatory reaction may not be induced in cells expressing the antigen protein.
- a third problem is that when administering mRNA to a living body, a transport carrier is often required to protect the mRNA from enzymatic degradation, but an adjuvant may affect the function of the transport carrier.
- Non-Patent Document 3 describes an mRNA vaccine in which mRNA is integrated with protamine, which is an adjuvant component.
- the first aspect of the present invention aims to provide a new method for stabilizing an mRNA transport carrier.
- the second and third aspects of the present invention aim to provide a new mRNA vaccine that enables efficient protein expression and immunity induction.
- mRNA can be functionalized by hybridizing RNA oligomer having a sequence complementary to mRNA to mRNA, and the present invention has been completed.
- the present inventors can chemically modify mRNA by chemically modifying an RNA oligomer having a sequence complementary to mRNA and hybridizing it to mRNA, thereby stabilizing the mRNA. It has been found that the transport carrier can be stabilized by mounting the mRNA on the transport carrier, and the first aspect of the present invention has been completed.
- the present inventors achieved both efficient protein expression and immune induction from mRNA by hybridizing to the mRNA an RNA oligomer having a sequence complementary to the poly A sequence of the mRNA encoding the antigen.
- the inventors have found out what can be done and have completed the second aspect of the present invention.
- the inventors hybridize a first RNA oligomer having a sequence complementary to the sequence of mRNA encoding the antigen to the mRNA, and a second sequence having a sequence complementary to the first RNA oligomer. It has been found that by hybridizing an RNA oligomer to a first RNA oligomer, both efficient protein expression and immunity induction from mRNA can be achieved, and the third aspect of the present invention has been completed.
- the present invention is as follows.
- a functionalized mRNA comprising double stranded RNA comprising mRNA and at least one modified RNA oligomer hybridized to the mRNA.
- the first aspect of the present invention is as follows. [1-1] A transport carrier for the mRNA containing mRNA encoding a target gene and at least one RNA oligomer hybridized to the mRNA, RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and A transport carrier comprising an RNA sequence that hybridizes to mRNA and is chemically modified.
- [1-1A] A transport carrier for the mRNA containing mRNA encoding a target gene and at least one RNA oligomer hybridized to the mRNA, RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and A transport carrier comprising an RNA sequence that hybridizes to mRNA and not chemically modified or chemically modified. [1-2] The transport carrier according to [1-1] or [1-1A] above, wherein the RNA sequence consists of a sequence of 15 to 23 bases.
- RNA sequence is a 17-base sequence.
- the chemical modification is performed at the 5 ′ end or 3 ′ end of the RNA oligomer sequence via an overhang sequence of 1 to 5 bases, [1-1] to [1- [3] The transport carrier according to any one of [3].
- the overhang sequence is a sequence of 2 bases.
- the chemical modification is modification with a hydrophobic group.
- the transport carrier according to [1-6] above, wherein the modification with the hydrophobic group is cholesterol modification.
- RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and A method for stabilizing a transport carrier, comprising an RNA sequence that hybridizes to mRNA and chemically modified.
- RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and A method for stabilizing a transport carrier, comprising an RNA sequence that hybridizes to mRNA and not chemically modified or chemically modified.
- Double-stranded RNA comprising mRNA encoding a target gene and at least one RNA oligomer hybridized to the mRNA, RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and Double-stranded RNA comprising an RNA sequence that hybridizes to mRNA and not chemically modified or chemically modified. [1-13] The double-stranded RNA according to [1-12] above, wherein the RNA sequence consists of a sequence of 15 to 23 bases.
- [1-14] The double-stranded RNA according to [1-13] above, wherein the RNA sequence consists of a 17-base sequence.
- the above chemical modification is performed at the 5 ′ end or 3 ′ end of the RNA oligomer sequence via an overhang sequence of 1 to 5 bases, [1-12] to [1- [14] The double-stranded RNA according to any one of [14].
- [1-16] The double-stranded RNA according to [1-15] above, wherein the overhang sequence is a 2-base sequence.
- [1-17] The double-stranded RNA according to any one of [1-12] to [1-16] above, wherein the chemical modification is modification with a hydrophobic group.
- [1-18] The double-stranded RNA according to [1-17] above, wherein the modification with the hydrophobic group is cholesterol modification.
- [1-19] The double-stranded RNA according to any one of [1-12 to [1-16] above, wherein the chemical modification is a polyethylene glycol modification.
- a pharmaceutical composition comprising the transport carrier according to any one of [1-20] and [1-21] above.
- the second aspect of the present invention is as follows.
- [2-1] A double-stranded RNA comprising an mRNA encoding an antigen and at least one RNA oligomer hybridized to at least a poly A sequence of the mRNA, wherein the at least one RNA oligomer is not chemically modified, mRNA vaccine.
- [2-1A] a double-stranded RNA comprising mRNA encoding an antigen and at least one RNA oligomer hybridized to at least a poly A sequence of the mRNA, wherein the at least one RNA oligomer is not chemically modified; or An mRNA vaccine that is chemically modified.
- RNA vaccine according to [2-1] or [2-1A] above, wherein the RNA oligomer consists of 10 to 500 base sequences.
- RNA vaccine according to any one of [2-1] to [2-2] above, wherein the RNA oligomer has a triphosphate structure at the 5 ′ end.
- RNA vaccine The double-stranded RNA according to any one of [2-1] to [2-3] above, wherein one RNA oligomer is hybridized to at least a poly A sequence of mRNA. mRNA vaccine.
- [2-6] The mRNA vaccine according to any one of [2-1] to [2-5], which is not used with an adjuvant.
- [2-7] The mRNA vaccine according to any one of [2-1] to [2-6] above, which is used for the prevention or treatment of a disease in a subject in need of the prevention or treatment of the disease.
- Disease prevention or treatment comprising administering to the subject in need of disease prevention or treatment the mRNA vaccine of any one of [2-1] to [2-6] above Method of treatment.
- the third aspect of the present invention is as follows.
- Double-stranded RNA comprising mRNA encoding an antigen, at least one first RNA oligomer hybridized to the mRNA, and a second RNA oligomer hybridized to the first RNA oligomer Including
- the first RNA oligomer is (A) a first RNA sequence consisting of a 12-40 base sequence complementary to the mRNA sequence and a second RNA sequence consisting of a 10-200 base sequence complementary to the second RNA oligomer sequence; An RNA sequence comprising in this order from the 5 ′ end, (B) 90% identity with a sequence of 12 to 40 bases complementary to the mRNA sequence and complementary to the sequence of the first RNA sequence and the second RNA oligomer that hybridize to the mRNA An RNA sequence comprising a second RNA sequence having at least 90% identity with a 10-200 base sequence and hybridizing to the second RNA oligomer in this order from the 5 ′ end, (C) a second
- the first RNA oligomer includes the RNA sequence of (a) or the RNA sequence of (b), and the second RNA oligomer has a triphosphate structure at the 5 ′ end, [3 The mRNA vaccine according to any one of [-1] to [3-3].
- the first RNA oligomer includes the RNA sequence of (c) or the RNA sequence of (d), and the first RNA oligomer has a triphosphate structure at the 5 ′ end, [3 The mRNA vaccine according to any one of [-1] to [3-3]. [3-6] The above [3-1] to [3-5], wherein the end of the double-stranded RNA on the side where the second RNA oligomer is hybridized to the first RNA oligomer is a blunt end The mRNA vaccine according to any one of the above. [3-7] The mRNA vaccine according to any one of [3-1] to [3-6] above, wherein the second RNA oligomer comprises a sequence of 10 to 200 bases.
- [3-8] The mRNA vaccine according to any one of [3-1] to [3-7] above, wherein the double-stranded RNA is in naked form.
- [3-9] The mRNA vaccine according to any one of [3-1] to [3-8], which is not used with an adjuvant.
- [3-10] The mRNA vaccine according to any one of the above [3-1] to [3-9] for use in the prevention or treatment of a disease in a subject in need of the prevention or treatment of the disease.
- the present invention can provide functionalized mRNA.
- the first aspect of the present invention provides a new method for stabilizing mRNA or mRNA transport carrier.
- the first aspect of the present invention can achieve relatively free mRNA modification in vivo while maintaining protein translation efficiency from mRNA. More preferably, the first aspect of the present invention can inhibit enzymatic degradation of mRNA in vivo.
- the second and third aspects of the present invention provide a new mRNA vaccine that enables efficient protein expression and immunity induction.
- the mRNA vaccine of the second and third aspects of the present invention is capable of antigen presentation and immunity induction without simultaneous administration of an adjuvant.
- the mRNA vaccine of the second and third aspects of the present invention can induce stronger cellular immunity.
- the second and third mRNA vaccines of the present invention can induce stronger humoral immunity than administration of mRNA alone.
- A PEG-PAsp (DET) + RNA oligo (-);
- B PEG-PAsp (DET)-Chol + RNA oligo (-);
- C PEG-PAsp (DET) + unmodified RNA oligo;
- D PEG -PAsp (DET) -Chol + unmodified RNA oligo;
- E PEG-PAsp (DET) + Chol-RNA oligo;
- F PEG-PAsp (DET) -Chol + Chol-RNA oligo. It is a figure which shows the influence on stability by hybridization to mRNA of Chol modification RNA oligomer.
- A PEG-PAsp (DET) -Chol
- B PEG-PAsp
- C PEG-PAsp
- D PEG-PAsp
- E PEG-PAsp
- A PEG-PAsp (DET) -Chol + oligo ( ⁇ );
- B PEG-PAsp (DET) -Chol + Chol oligo;
- C PEG-PAsp (DET) + oligo ( ⁇ );
- D PEG-PAsp (DET) + Chol oligo.
- FBS condition 10v / v%. It is a figure which shows the influence on the protein translation efficiency at the time of introduce
- the underlined part is open reading frame.
- the underlined part is open reading frame. This is the sequence of poly U produced in the example (SEQ ID NO: 56).
- a functionalized mRNA comprising double stranded RNA comprising mRNA and at least one modified RNA oligomer hybridized to the mRNA.
- a functionalized mRNA comprising double stranded RNA comprising mRNA and at least one modified RNA oligomer hybridized to the mRNA.
- First aspect of the present invention 1.1. Outline of the First Aspect of the Invention Conventionally, it has been difficult to design a free chemical modification in the base modification of mRNA. Therefore, the present inventors considered that it is possible to chemically modify mRNA by chemically modifying an RNA oligomer having a sequence complementary to mRNA and hybridizing it to mRNA (FIG. 1). . In this case, since the mRNA itself is natural, it was expected that the translation process was not hindered and free chemical modification was possible. On the other hand, since there was a concern about the failure of the translation process due to hybridization, first, RNA oligomers of various chain lengths were hybridized, and the influence on translation efficiency was examined.
- the mRNA-carrying transport carrier for example, polymer micelle
- the stabilization effect by such a Chol modification oligomer is acquired in the composition of several polymeric micelle (FIG. 11), and it can be said that it is a highly versatile platform for improving the enzyme resistance of mRNA.
- RNA oligomer modification of the Chol group to either the 5 'or 3' end did not significantly affect the stability and efficiency of protein expression from mRNA (Fig. 8). It is also possible to insert an overhang sequence that does not hybridize between the complementary sequence of the RNA oligomer and the Chol group. For example, when a block copolymer modified with Chol is used, there is a tendency that a higher stabilization effect is obtained in the case where there is an overhang sequence of 2 bases compared to the case where there is no overhang sequence ( FIG. 4 (A) and (C)). On the other hand, when a block copolymer in which Chol was not modified was used, a more excellent stabilizing effect was obtained even without an overhang sequence (FIGS. 4B and 4D).
- mRNA can be chemically modified freely by chemically modifying RNA oligomer and hybridizing it to mRNA.
- chemically modified mRNA since there is a concern that the efficiency of translation from mRNA may decrease due to hybridization, studies have not been made to hybridize chemically modified mRNA for use in the inhibition of enzymatic degradation of mRNA. .
- RNA oligomers of various chain lengths As a composition having a chain length capable of forming a stable hybrid and not affecting translation efficiency, a complementary sequence of 12 to 40 bases. I found that something with is good. In addition, in the stabilization of polymer micelles using hybridization of chemically modified RNA oligomers, it was found that the chemical modification position may be 5 ′ end or 3 ′ end (FIG. 8). It was also found that there may be no overhang sequence between the complementary sequence of the RNA oligomer and the Chol group, or there may be an overhang sequence of 1 to 5 bases.
- the first aspect of the present invention is a versatile technique capable of suppressing the enzymatic degradation of mRNA in mRNA itself or various transport carriers (for example, polymer micelles).
- a first aspect of the present invention is a double-stranded RNA comprising mRNA encoding a target gene and at least one RNA oligomer hybridized to the mRNA, RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and Provided is a double-stranded RNA comprising an RNA sequence that hybridizes to mRNA and not chemically modified or chemically modified.
- Double-stranded RNA may be encapsulated in a transport carrier.
- the double-stranded RNA may not be encapsulated in the transport carrier, that is, it may be in naked form.
- the first aspect of the present invention is a transport carrier for the mRNA containing mRNA encoding a target gene and at least one RNA oligomer hybridized to the mRNA, RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and Provided is a transport carrier comprising an RNA sequence that hybridizes to mRNA and is either not chemically modified or chemically modified.
- the transport carrier is not particularly limited as long as it can enclose nucleic acid and can be delivered to a suitable location in the body of the subject.
- the transport carrier is, for example, a polymer micelle, a lipidic mRNA carrier, or a cationic polymer complex, and more preferably a polymer micelle or a lipidic mRNA carrier.
- the polymer micelle has a two-layer structure of an inner core formed of condensed nucleic acid and a cationic polymer and an outer shell formed of a hydrophilic polymer.
- the cationic polymer is, for example, a polyamino acid derivative.
- the hydrophilic polymer is, for example, polyethylene glycol (“PEG”).
- the inner core physically or chemically encapsulates the mRNA.
- the outer shell delivers mRNA encapsulated in the inner shell to a predetermined tissue due to its physicochemical properties.
- Polymeric micelles can enter cells by endocytosis.
- polymer micelle for example, an interaction between a polycation and a nucleic acid on a block polymer (polyion complex (“PIC”)) can be used, and a hybrid micelle of an inorganic molecule can also be used.
- PIC polyion complex
- PIC polymer micelles examples include PEG micelles formed by polymolecular association of PEG-PAsp (DET) -Chol, PEG-PAsp (DET), PEG-PLys and mRNA (see Examples below) and , PAsp (TET), PAsp (TEP) using another polycation as a block copolymer (Uchida, S., et al., Biomaterials (2016) 82, p.221-228) and triblock copolymer Examples include those using a polymer (Osawa, S., et al. Biomacromolecules 17, p354-361 (2016)).
- hybrid micelles with inorganic molecules include PEGylated calcium phosphate (CaP) particles (Pittela, et al., Biomaterials (2011) 32, p. 3106-3114), PEGylated silica particles (Miyata, K., et al. Biomaterials (2010) 31, p4764-4770).
- CaP PEGylated calcium phosphate
- the lipidic mRNA carrier is formed using lipid or cationic lipid as a carrier, and the mRNA is in an encapsulated or bound form.
- lipid or cationic lipid for example, N- [1- (2,3-dioleyloxy) propyl] -N, N, N-trimethylammonium chloride (DOTMA), 2,3-dioleyloxy-N- [2- (sperminecarboxamide) Ethyl] -N, N-dimethyl-1-propanaminium trifluoroacetic acid (DOSPA), 1,2-dioleoyloxy-3- (trimethylammonium) propane (DOTAP), N- [1- (2,3 -Dimyristyloxy) propyl] -N, N-dimethyl-N- (2-hydroxyethyl) ammonium bromide (DMRIE) or DC-Cholesterol; cationic lipids; distearoylphosphatidylcholine (DSPC) or
- the cationic polymer complex is, for example, a mixture of linear or branched polyethyleneimine, polylysine, polyarginine, chitosan derivative, polymethacrylic acid derivative and mRNA.
- the amount of mRNA encapsulated in the transport carrier is, for example, 0.5-200 in the ratio of the cation charge (+) in the transport carrier to the anion charge ( ⁇ ) of the mRNA (+/ ⁇ ratio). It is preferably 1 to 50, and more preferably 1 to 10.
- the target gene can be appropriately selected by those skilled in the art according to the purpose.
- the target gene is, for example, a reporter gene, a growth factor gene, a cell growth factor gene, a cell growth inhibitory factor gene, a cell death promoting factor gene, a cell death inhibitory factor gene, a cancer suppressor gene, a transcription factor gene, a genome editing gene or a vaccine antigen It is a gene.
- a disease or condition in the subject can be treated by administering a transport carrier encapsulating mRNA encoding the growth factor gene of the specific cell to a subject in need of growing the specific cell. it can.
- reporters include photoproteins and fluorescent proteins.
- growth factors examples include epidermal growth factor (EGF), insulin-like growth factor (IGF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), granulocyte colony Stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), platelet derived growth factor (PDGF), erythropoietin (EPO), thrombopoietin (TPO), basic fibroblast growth factor (bFGF or FGF- 2) and hepatocyte growth factor (HGF).
- EGF epidermal growth factor
- IGF insulin-like growth factor
- NGF nerve growth factor
- BDNF brain-derived neurotrophic factor
- VEGF vascular endothelial growth factor
- G-CSF granulocyte colony Stimulating factor
- GM-CSF granulocyte macrophage colony stimulating factor
- PDGF platelet derived growth factor
- EPO erythrop
- Examples of the cell growth inhibitory factor include p21, p17, p16 and p53.
- cell death promoting factor examples include Smac / Diablo, apoptosis-inducing factor (AIF), HtrA2, Bad, Bim, Bax, p53, caspase 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (Eg, caspase 2, 3, 6, 7, 8, 9 and 10, preferably caspase 3, 6 and 7), Fas ligand (FasL), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and FoxO1.
- AIF apoptosis-inducing factor
- HtrA2 HtrA2
- Bad Bim
- Bax Bax
- p53 caspase 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10
- caspase 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 Eg, caspase 2, 3, 6, 7, 8, 9 and 10, preferably caspase 3, 6 and 7
- Fas ligand Fas ligand
- TRAIL tumor necrosis factor-related apoptosis-inducing
- cell death inhibitory factor examples include anti-apoptotic factors (for example, FLIP, Mcl-1, Xiap, crmA, Bcl-2 and Bcl-xL).
- anti-apoptotic factors for example, FLIP, Mcl-1, Xiap, crmA, Bcl-2 and Bcl-xL.
- tumor suppressor gene examples include p53, retinoblastoma gene (Rb), colorectal adenomatous gene (APC), neurofibromatosis type 1 gene (NF1), neurofibromatosis type 2 gene (NF2), and WT1.
- Rb retinoblastoma gene
- APC colorectal adenomatous gene
- NF1 neurofibromatosis type 1 gene
- NF2 neurofibromatosis type 2 gene
- transcription factors examples include Runt-related transcription factor 1 (Runx1), p53, c-fos, c-Jun, CREB, C / EBP, MyoD, c-Myc, c-Myb, Oct3 / 4, NF- ⁇ B, NF-AT, Mef-2 and extracellular signal response factor (SRF).
- Runx1 Runt-related transcription factor 1
- p53 p53
- c-fos c-Jun
- CREB C / EBP
- MyoD MyoD
- c-Myc c-Myb
- Oct3 / 4 NF- ⁇ B
- Mef-2 extracellular signal response factor
- Genomic editing genes include, for example, zinc fingerer nuclease (ZNF), transcribable activator like effector nuclease (TALEN), and clustered, regularly interspaced, shortISCR.
- ZNF zinc fingerer nuclease
- TALEN transcribable activator like effector nuclease
- clustered, regularly interspaced, shortISCR clustered, regularly interspaced, shortISCR.
- vaccine antigen genes include pathogen antigens and tumor-specific antigens.
- mRNA means messenger RNA and usually comprises a 5 ′ untranslated region (5′UTR), a coding region and a 3 ′ untranslated region (3′UTR).
- the mRNA usually further comprises a cap structure (5 ′ Cap) at the 5 ′ end and a poly A sequence at the 3 ′ end.
- the mRNA used here may be any of the following. (1) mRNA containing 5 ′ Cap, 5 ′ UTR, coding region, 3 ′ UTR, and poly A in this order. (2) mRNA containing 5′Cap, 5′UTR, coding region, and poly A in this order. (3) mRNA containing 5′UTR, coding region, 3′UTR, and poly A in this order.
- mRNA containing 5′UTR, coding region, and poly A in this order (5) mRNA containing 5′Cap, 5′UTR, coding region, and 3′UTR in this order. (6) mRNA containing 5 ′ Cap, 5 ′ UTR and coding region in this order. (7) mRNA containing 5′UTR, coding region, and 3′UTR in this order. (8) mRNA containing 5′UTR and coding region in this order.
- MRNA encoding the target gene can be prepared by transcription of the template DNA encoding the target gene in an in vitro environment by a known method. For example, it can be produced according to the method described in Blood 108 (13) (2006) 4009-17. Specifically, a template DNA in which a poly A / T chain is incorporated downstream of a protein coding sequence is cleaved immediately downstream of the poly A / T chain and placed in a buffer solution containing a translation enzyme, a nucleoside, and a 5 ′ cap analog. In vitro transcription can be performed, and then mRNA can be purified. A more specific method for preparing mRNA is as described in Examples below.
- chemical modification of the base of the mRNA itself is not performed. In this case, since the mRNA itself is natural, it can be expected that the translation process is hardly impaired. In some other embodiments, chemical modification of the base of the mRNA itself is performed. It is known that chemical modification of the base of mRNA itself can improve the enzyme resistance of mRNA or reduce immunogenicity, for example.
- Such chemically modified bases of mRNA itself include, for example, methylated bases (eg, 5-methylcytosine), sulfur modified bases (eg, 2-thiouridine), pseudouridine, N1 methyl pseudouridine, and 5 methoxyuridine. .
- RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and An RNA strand comprising an RNA sequence that hybridizes to mRNA.
- RNA sequence having 90% or more identity is, for example, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, It is 99.7% or more, 99.8% or more, or 99.9% or more.
- identity of the RNA sequence can be determined using an analysis program such as BLAST (see, for example, Altzshul SF et al., J. Mol. Biol. 215, 403 (1990)). When using BLAST, the default parameters of each program are used.
- Hybridizes to mRNA means that an RNA oligomer hybridizes to mRNA under the hybridization conditions described below.
- RNA oligomers are designed to hybridize to a sequence of 12 to 40 bases of mRNA.
- the RNA oligomer sequence consists of a 12-30 base sequence complementary to the mRNA sequence. More preferably, the sequence of the RNA oligomer consists of a sequence of 15 to 23 bases complementary to the sequence of mRNA. More preferably, the sequence of the RNA oligomer is a 17-base sequence complementary to the sequence of mRNA.
- the position in the mRNA to which the RNA oligomer is hybridized may be any position of 5'UTR, coding region, 3'UTR, and poly A sequence. It is desirable that the RNA oligomer is designed so that the secondary structure of the mRNA is predicted and the mRNA chain is hybridized to a portion having no secondary structure. That is, the RNA oligomer is preferably designed so as to hybridize to a portion having no secondary structure in the entire mRNA sequence. Examples of the software for predicting the secondary structure of mRNA include those described in the examples described later.
- the RNA oligomer is designed to hybridize to the poly A sequence of mRNA.
- Oligo RNA chemical modification may be performed without an overhang sequence, or may be performed through an overhang sequence.
- the “overhang sequence” is a sequence that does not hybridize to mRNA.
- the oligo RNA preferably comprises only the RNA sequence (a) or (b). In this case, the chemical modification is performed at the 5 'end or 3' end of the sequence of the RNA oligomer.
- the transport carrier is a transport carrier that is not modified with a hydrophobic group (eg, a block copolymer that is not modified with a hydrophobic group)
- the chemical modification of the oligo RNA is an overhang sequence. Do not go through.
- the oligo RNA when the chemical modification is performed via an overhang sequence, preferably comprises the RNA sequence (a) or (b) and an overhang sequence.
- chemical modification is carried out via an overhang sequence of 1 to 5 bases at the 5 ′ end or 3 ′ end of the RNA sequence of the RNA oligomer (a) or (b).
- the chain length of the overhang sequence is preferably 1 to 4 bases, more preferably 1 to 3 bases, and further preferably 2 bases. If the chain length of the overhang sequence is 1 to 5 bases, a relatively high mRNA stabilizing effect can be expected.
- the transport carrier is a transport carrier modified with a hydrophobic group (eg, a block copolymer modified with a hydrophobic group)
- the chemical modification of the oligo RNA is 1-5 bases.
- the RNA sequence of (a) or (b) is made at the 5 ′ end or 3 ′ end of the RNA oligomer.
- RNA oligomer either the 5 ′ end or the 3 ′ end of the RNA sequence (a) or (b) may be chemically modified via an overhang sequence.
- an RNA oligomer chemically modified through an overhang sequence may be referred to as a “chemically modified oligomer”.
- a chemical modification is, for example, a modification that can stabilize a naked double-stranded RNA or mRNA transport carrier.
- Examples of such chemical modification include modification with a hydrophobic group and modification with polyethylene glycol.
- Examples of the modification with a hydrophobic group include cholesterol modification and tocopherol modification.
- the modification with a hydrophobic group is a cholesterol modification.
- the modification with a hydrophobic group can be carried out, for example, by the phosphoramidite method described in (SL BEAucage, et al., Tetrahedron Letters (1981) 22, p. 1859-1862) or a method analogous thereto. .
- Modification with a hydrophobic group can be performed, for example, as follows. After synthesizing the RNA oligomer, an RNA oligomer having a hydrophobic group introduced at the 5 ′ end can be obtained by reacting the amidite hydrophobic group with the 5 ′ terminal OH group of the RNA oligomer.
- transduced the hydrophobic group into 3 'terminal can be obtained by performing RNA synthesis by the phosphoramidite method from the hydrophobic group of OH group terminal.
- chemical modification does not include the 5′-terminal triphosphate structure.
- an RNA oligomer is synthesized using an initiator such as DMS (O) MT-AMINO-MODIFIER (GLENRESERCH) and deprotected to obtain a 5'-terminal aminated RNA oligomer.
- a PEGylated RNA oligomer can be obtained by reacting the 5'-terminal aminated RNA oligo with, for example, PEG-N-hydroxysuccinimide.
- the polyethylene glycol to be used include linear PEG having a weight average molecular weight of 1,000 to 80,000, and branched PEG having the same molecular weight such as 2-branch, 4-branch, and 8-branch. .
- the number of non-chemically modified RNA oligomers or chemically modified RNA oligomers to be hybridized to mRNA is at least 1, preferably 1-50, more preferably 1-15, and still more preferably. 1 to 5 pieces. As the number of RNA oligomers is increased, the stability of mRNA is further improved. If the number of RNA oligomers is in the range of 1 to 50, the translation efficiency of mRNA can be maintained at a relatively high level.
- each unmodified RNA oligomer or chemically modified RNA oligomer does not overlap on the mRNA.
- Hybridization of RNA oligomers to mRNA can be performed by known methods and conditions. In hybridization, after heating and allowing to stand for a certain time, the temperature is gradually lowered. Heating is performed for the purpose of binding mRNA and oligomer more efficiently by releasing complementary bonds existing in and between mRNA and oligomer molecules. If proper hybridization is ensured, the temperature time can be appropriately adjusted. The slower the temperature drop, the more specific the hybridization. Further, the oligomer chain length does not greatly affect the setting of hybridization conditions. Conditions should be set as appropriate while evaluating the hybridization efficiency. For example, the methods and conditions described in the examples described later can be mentioned.
- the first aspect of the present invention includes hybridizing at least one RNA oligomer to mRNA encoding a target gene to obtain double-stranded RNA, RNA oligomers (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and Provided is a method for stabilizing mRNA, comprising an RNA sequence that hybridizes to mRNA and that is not chemically modified or chemically modified.
- the RNA oligomer not chemically modified or the mRNA hybridized with the chemically modified RNA oligomer may be encapsulated in a transport carrier.
- the RNA oligomer not chemically modified or the mRNA hybridized with the chemically modified RNA oligomer may not be encapsulated in the transport carrier, that is, may be in the form of naked.
- the RNA oligomer not chemically modified or the mRNA hybridized with the chemically modified RNA oligomer is encapsulated in a transport carrier.
- the first aspect of the present invention includes encapsulating mRNA encoding a target gene and at least one RNA oligomer hybridized with the mRNA in a transport carrier, (A) an RNA sequence comprising a sequence of 12 to 40 bases complementary to the sequence of mRNA, or (b) 90% or more identity with a sequence of 12 to 40 bases complementary to the sequence of mRNA, and Also provided is a method for stabilizing a transport carrier that includes an RNA sequence that hybridizes to mRNA and that is unmodified or chemically modified.
- mRNA, RNA oligomer, transport carrier, chemical modification, etc. used in the stabilization method are as described in the description of the transport carrier.
- the first aspect of the present invention provides a pharmaceutical composition containing the double-stranded RNA or transport carrier.
- the pharmaceutical composition is used to deliver mRNA or a transport carrier encapsulating mRNA into the body of a subject.
- a “subject” is a human or non-human organism, such as avian and non-human mammals (eg, cows, monkeys, cats, mice, rats, guinea pigs, hamsters, pigs, dogs, rabbits, sheep, and horses). is there.
- avian and non-human mammals eg, cows, monkeys, cats, mice, rats, guinea pigs, hamsters, pigs, dogs, rabbits, sheep, and horses.
- the pharmaceutical composition is administered intravenously, intraarterially, orally, or intratissue (eg, intravesical, intrathoracic, intraperitoneal, intraocular, intracerebral) or transdermal administration to a subject.
- intravenous administration, transdermal administration, and transmucosal administration are desirable.
- These dosage forms are suitable for administration, for example, various injections, oral preparations, drops, inhalants, eye drops, ointments, lotions, and suppositories.
- Each condition such as dosage, number of administrations, and administration period is appropriately determined by those skilled in the art after considering the type of mRNA, dosage form, subject state such as age and weight, administration route, nature and degree of disease. Can be set.
- the pharmaceutical composition can be used for treatment of introducing mRNA encoding a desired gene into cells causing various diseases. Therefore, the 1st aspect of this invention can also provide the treatment method of various diseases including administering a pharmaceutical composition to the subject which needs treatment of various diseases.
- the conditions such as the dose, the number of administrations and the administration period are the same as described above.
- Various diseases to be treated include, for example, cancer, viral diseases, metabolic diseases, cardiovascular diseases, neurological diseases, renal urological diseases, hematological malignancies, diseases for which promotion or suppression of apoptosis is desired, collagen diseases, respiratory diseases And gastrointestinal diseases.
- excipients for pharmaceutical compositions, excipients, fillers, extenders, binders, wetting agents, disintegrants, lubricants, surfactants, dispersants, buffers, preservatives, solubilizers commonly used in drug production
- Preservatives, flavoring agents, soothing agents, stabilizers, tonicity agents and the like can be appropriately selected and used according to conventional methods.
- an intravenous injection for example, it is provided in the state of a unit dose ampoule or a multi-dose container.
- the dosage of mRNA is, for example, 1 for adults, taking into account the type of mRNA, dosage form, subject condition such as age and weight, route of administration, nature and extent of disease. Within the range of 0.1 mg to 5 g / human per day, preferably within the range of 1 mg to 2 g.
- This dosage may vary depending on the type of target disease, dosage form, and target molecule. Therefore, in some cases, a lower dose may be sufficient, and conversely, a higher dose may be required. Moreover, it can be administered once to several times a day or at intervals of 1 day to several days.
- the mRNA delivery kit according to the first aspect of the present invention is characterized in that it contains mRNA hybridized with the above-mentioned RNA oligomer not chemically modified or chemically modified RNA oligomer.
- the RNA oligomer not chemically modified or the mRNA hybridized with the chemically modified RNA oligomer may be encapsulated in a transport carrier.
- the RNA oligomer not chemically modified or the mRNA hybridized with the chemically modified RNA oligomer may not be encapsulated in the transport carrier, that is, may be in the form of naked.
- the RNA oligomer not chemically modified or the mRNA hybridized with the chemically modified RNA oligomer is encapsulated in a transport carrier.
- the former kit for mRNA delivery according to the first aspect of the present invention is characterized by comprising a transport carrier.
- the kit can be preferably used for, for example, a method for treating various diseases using mRNA or a transport carrier that is hybridized with the RNA oligomer not chemically modified or the chemically modified RNA oligomer.
- the state of preservation of the RNA oligomer not chemically modified or the mRNA or transport carrier hybridized with the chemically modified RNA oligomer is not limited, taking into account its stability (preservation) and ease of use.
- a state such as solution or powder can be selected.
- the kit may contain other components in addition to the mRNA or transport carrier hybridized with the unmodified RNA oligomer or chemically modified RNA oligomer.
- other components include various buffers and instructions for use (use manual).
- Second aspect of the present invention 2.1. Outline of Second Aspect of Present Invention Since mRNA itself has low immunogenicity, it hardly causes an inflammatory reaction. Therefore, conventional vaccines using single-stranded mRNA cannot avoid the combined use of adjuvants for effectively inducing an inflammatory reaction.
- RNA molecules themselves exist in a living body and do not use foreign substances it is considered that relatively high safety is ensured when double-stranded RNA is used.
- the second aspect of the present invention includes a double-stranded RNA comprising mRNA encoding an antigen and at least one RNA oligomer hybridized to at least a poly A sequence of the mRNA, wherein the at least one RNA oligomer is Provided are mRNA vaccines that are not chemically modified or chemically modified.
- the mRNA vaccine of the second aspect of the present invention can achieve both efficient protein expression and immunity induction ability.
- the ability of the mRNA vaccine of the second aspect of the present invention to actually improve the vaccine effect was evaluated by focusing attention on cellular immunity in terms of immunity induction ability in mice (FIG. 25 (A)).
- ovalbumin (OVA) was used as a model antigen, and OVA-expressed mRNA was administered to the inguinal lymph nodes of mice. Subsequently, spleen cells one week later were collected, and the number of cells specifically reacting with OVA was evaluated by the ELISPOT method. Then, when administered to a lymph node, mRNA obtained by hybridizing a complementary RNA (poly U) to a poly A sequence significantly increases antigen-specific cellular immunity compared to unhybridized mRNA. It became clear that it induced (FIG. 25 (B)). Thus, it was demonstrated that the cellular immunity induction effect is improved by using the mRNA vaccine of the second aspect of the present invention.
- mice were evaluated for humoral immunity using the mRNA vaccine of the second aspect of the present invention (FIG. 26 (A)), and a complementary strand RNA (poly U) was hybridized to the poly A sequence. It was clarified that the treated mRNA induces antigen-specific humoral immunity significantly stronger than the unhybridized mRNA (FIG. 26 (B)).
- RNA double stranded RNA induces a strong inflammatory reaction when introduced into cells.
- binding of a full-length complementary strand to mRNA inhibits protein expression from mRNA.
- an inflammatory response can be induced while maintaining protein expression from mRNA by site-specific hybridization of complementary strands centering on the poly A sequence.
- mRNA mRNA means messenger RNA and usually comprises a 5 ′ untranslated region (5′UTR), a coding region and a 3 ′ untranslated region (3′UTR).
- the mRNA usually further comprises a cap structure (5 ′ Cap) at the 5 ′ end and a poly A sequence at the 3 ′ end.
- the mRNA used for the mRNA vaccine may be any of the following. (1) mRNA containing 5 ′ Cap, 5 ′ UTR, coding region, 3 ′ UTR, and poly A in this order. (2) mRNA containing 5′Cap, 5′UTR, coding region, and poly A in this order. (3) mRNA containing 5′UTR, coding region, 3′UTR, and poly A in this order.
- the mRNA used for the mRNA vaccine can be prepared by transcription of a template DNA encoding the target gene in an in vitro environment by a known method. For example, it can be produced according to the method described in Blood 108 (13) (2006) 4009-17. Specifically, a template DNA in which a poly A / T chain is incorporated downstream of a protein coding sequence is cleaved immediately downstream of the poly A / T chain and placed in a buffer solution containing a translation enzyme, a nucleoside, and a 5 ′ cap analog. In vitro transcription is performed, and then mRNA is purified. A more specific method for preparing mRNA is as described in Examples below.
- the antigen encoded by the coding region of mRNA can be arbitrarily selected from known antigens suitable for inducing an immune response. More specifically, examples of the antigen include tumor antigens, virus-derived antigens, bacteria-derived antigens, fungal-derived antigens, protozoan-derived antigens, animal-derived antigens, plant-derived antigens, and autoimmune disease self-antigens.
- the antigen encoded by the mRNA may be one antigen, or two or more (eg, 2, 3, 4, or 5 or more) identical or different antigens. In some aspects of the second aspect of the invention, the antigen encoded by the mRNA is a single antigen.
- the length of the poly A sequence of mRNA is, for example, 10 to 500 bases, preferably 30 to 300 bases, and more preferably 60 to 250 bases.
- the 5'UTR and 3'UTR sequences of the mRNA may have 100% sequence identity with the naturally occurring sequence, or may be partially or wholly in other 5'UTR and / or 3'UTR sequences. It may be replaced with a sequence.
- Other 5 ′ UTR and / or 3 ′ UTR sequences include, for example, 5 ′ UTR and / or 3 ′ UTR sequences of mRNA encoding globin, hydrosteroid (17- ⁇ ) dehydrogenase 4, or albumin. .
- the mRNA is not modified. In this case, since the mRNA itself is natural, it can be expected that the translation process is hardly impaired.
- the mRNA is modified to further stabilize the mRNA.
- the modification of mRNA include chemical modification of the base of mRNA, modification of the G / C content of the coding region of mRNA, modification of the Cap structure of mRNA, and the like.
- the chemical modification of the base of mRNA is, for example, known to improve the enzyme resistance of mRNA.
- Such chemically modified bases of mRNA itself include, for example, methylated bases (eg, 5-methylcytosine), sulfur modified bases (eg, 2-thiouridine), pseudouridine, N1 methyl pseudouridine, and 5-methoxyuridine. It is done.
- the modification of the G / C content of the coding region of mRNA is to modify the content of G (guanine) / C (cytosine) so that more stable mRNA can be obtained.
- Modification of the Cap structure of mRNA is also known to make the 2 ′ position of the first or second ribose on the 5 ′ side a methoxy group, thereby improving the expression efficiency.
- Preparation and modification of mRNA can be performed by a known method or a method analogous thereto.
- RNA oligomer In the second aspect of the present invention, at least one RNA oligomer is hybridized to at least the poly A sequence of mRNA. The RNA oligomer does not contain chemical modification.
- sequence of mRNA to which one RNA oligomer hybridizes is, for example, one of the following sequences.
- RNA oligomer hybridizes to the whole (100%) or a part of the poly A sequence, but the sequence immediately before that (ie, 3′UTR)
- the RNA oligomer is designed so that the RNA oligomer does not hybridize to the coding region.
- a part of the poly A sequence has a base length of more than 0% and less than 100% of the total length of the poly A sequence, for example, a base length of 10 bases or more (preferably a base length of 17 bases or more). Is an array.
- the poly A sequence portion of the mRNA preferably has a complementary sequence of 17 bases or more to which the RNA oligomer hybridizes.
- the sequence in which one RNA oligomer hybridizes is (2) a continuous sequence in the 3′UTR of the mRNA and the poly A sequence. It may be.
- the RNA oligomer is designed so that one RNA oligomer hybridizes to the entire (100%) or part of the poly A sequence and a part of the 3′UTR sequence immediately before that.
- one RNA oligomer is, for example, a base length of more than 0% and less than 100% of the total length of the poly A sequence, and a base length of, for example, 10 bases or more (for example, 10, 11, 12, 13, 14 , 15, 16 or 17 base length or more, preferably 17 base length or more) and a sequence having a base length of more than 0% and less than 100% of the total length of the immediately preceding 3′UTR sequence.
- the poly A sequence portion and the 3 'UTR sequence portion of mRNA have a complementary sequence of 17 bases or more in total, to which the RNA oligomer hybridizes.
- the shorter the 3′UTR sequence portion of mRNA to which the RNA oligomer hybridizes is, the shorter, for example, 1 to 30 bases in length, preferably 1 to 25 bases in length, more preferably 1 to 2 bases in length. It is.
- the sequence to which one RNA oligomer hybridizes may be (3) a continuous sequence in the mRNA coding sequence and the poly A sequence.
- the RNA oligomer is designed so that one RNA oligomer hybridizes to the whole (100%) or a part of the poly A sequence and a part of the coding sequence immediately before that.
- one RNA oligomer is, for example, a base length of more than 0% and less than 100% of the total length of the poly A sequence, and a base length of, for example, 10 bases or more (for example, 10, 11, 12, 13, 14 , 15, 16 or 17 base length or more, preferably 17 base length or more) and a sequence having a base length of more than 0% and less than 100% of the total length of the immediately preceding coding sequence.
- the poly A sequence portion and the coding sequence portion of mRNA preferably have a complementary sequence of 17 bases or more in total to which the RNA oligomer hybridizes.
- the coding sequence portion of mRNA to which the RNA oligomer hybridizes is preferably as short as possible, for example, 1 to 30 bases in length, preferably 1 to 25 bases in length, more preferably 1 to 2 bases in length. .
- RNA oligomer examples include the following. (A) an RNA oligomer having a sequence complementary to the continuous sequence of any one of (1) to (3) above, or (B) An RNA oligomer having an RNA sequence having 90% or more identity with a sequence complementary to any of the continuous sequences of (1) to (3) above and hybridizing to mRNA.
- RNA sequence having 90% or more identity is, for example, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, It is 99.7% or more, 99.8% or more, or 99.9% or more. In general, the larger the numerical value of identity, the better.
- the identity of the RNA sequence can be determined using an analysis program such as BLAST (see, for example, Altzshul SF et al., J. Mol. Biol. 215, 403 (1990)). When using BLAST, the default parameters of each program are used. “Hybridizes to mRNA” means that an RNA oligomer hybridizes to mRNA under the hybridization conditions described below.
- the RNA oligomer may further contain other sequences, or may not contain other sequences.
- the “other sequence” is, for example, a promoter sequence, a restriction enzyme sequence, or other sequences that are unavoidably left when designing an RNA oligomer, or a part thereof.
- the base length of “other sequence” is, for example, 1 to 30 bases, preferably 1 to 25 bases, and more preferably 1 to 2 bases.
- the RNA oligomer preferably comprises a sequence of at least 10 bases, more preferably comprises a sequence of at least 17 bases, further preferably comprises a sequence of at least 30 bases, and particularly preferably comprises a sequence of at least 60 bases.
- the RNA oligomer preferably consists of a sequence of 10 to 500 bases, more preferably a sequence of 17 bases to 500 bases, and even more preferably a sequence of 30 to 300 bases. Particularly preferably, it consists of a sequence of 60 to 250 bases.
- the base length of the RNA oligomer can be appropriately designed in consideration of the length of the poly A sequence of mRNA. Some embodiments of RNA oligomers are those that do not contain chemical modifications.
- the chemical modification include modification with a hydrophobic group.
- the modification with a hydrophobic group include cholesterol modification and tocopherol modification.
- the chemical modification include polyethylene glycol modification.
- the definition of “chemical modification” does not include the 5′-terminal triphosphate structure.
- the RNA oligomer can be prepared by a known method or a method analogous thereto.
- the RNA oligomer is prepared from the template DNA by in vitro transcription.
- RNA oligomers can be prepared in substantially the same way as the above-mentioned mRNA preparation, but mRNA has a 5 ′ cap analog added during transcription, whereas RNA oligomer preparation. At this time, the cap analog is not added.
- an RNA oligomer When an RNA oligomer is thus biologically prepared, it can have a triphosphate structure at the 5 'end. The method for removing triphosphoric acid is as described later.
- Double stranded RNA is obtained by hybridizing at least one of the aforementioned RNA oligomers to the aforementioned mRNA.
- Double-stranded RNA can be prepared by hybridization of mRNA and RNA oligomer. More specifically, the hybridization can be performed under the conditions described in Examples described later or conditions equivalent thereto.
- the number of RNA oligomers to be hybridized to one mRNA is at least 1, preferably 1 to 5, more preferably 1 to 3, further preferably 1 to 2, especially Preferably, it is one.
- Hybridization of RNA oligomers to mRNA can be performed by known methods and conditions. More specifically, in hybridization, the temperature is gradually lowered after heating and allowing to stand for a certain period of time. Heating is performed for the purpose of binding mRNA and oligomer more efficiently by releasing complementary bonds existing in and between mRNA and oligomer molecules. If proper hybridization is ensured, the temperature time can be appropriately adjusted. In particular, poly A and poly U are unlikely to be combined with other sequences in advance, and more gentle heating conditions can be set. The slower the temperature drop, the more specific the hybridization. Further, the oligomer chain length does not greatly affect the setting of hybridization conditions. Conditions should be set as appropriate while evaluating the hybridization efficiency. For example, the methods and conditions described in the examples described later can be mentioned.
- the double stranded RNA has a triphosphate structure at the 5 ′ end of the RNA oligomer.
- a triphosphate structure at the 5 ′ end of the RNA oligomer By having a triphosphate structure at the 5 ′ end of the RNA oligomer, a stronger inflammatory reaction can be induced.
- the double stranded RNA does not have a triphosphate structure at the 5 ′ end of the RNA oligomer.
- the method for removing triphosphorylation can be carried out by a known method or a method analogous thereto. As a method for removing triphosphorylation, for example, as in Examples described later, a method using an artificial phosphatase (New England Biolabs, cat. No. M0289S) can be mentioned.
- the double stranded RNA is in naked form. That is, double-stranded RNA is not accompanied by a transport carrier. In some other embodiments, the double-stranded RNA is in a form encapsulated in a transport carrier.
- the transport carrier is not particularly limited as long as it can enclose the double-stranded mRNA and deliver it to a suitable site in the body of the subject.
- the transport carrier is a lipidic mRNA carrier or a cationic polymer complex, more preferably a polymeric micelle or a lipidic mRNA carrier.
- the polymer micelle has a two-layer structure of an inner core formed of condensed nucleic acid and a cationic polymer and an outer shell formed of a hydrophilic polymer.
- the cationic polymer is, for example, a polyamino acid derivative.
- the hydrophilic polymer is, for example, polyethylene glycol (“PEG”).
- the inner core physically or chemically encapsulates the mRNA.
- the outer shell delivers mRNA encapsulated in the inner shell to a predetermined tissue due to its physicochemical properties.
- Polymeric micelles can enter cells by endocytosis.
- the polymer micelle can use, for example, a combined action of a polycation and a nucleic acid (polyion complex (“PIC”)) on a block polymer, or a hybrid micelle of the polymer and an inorganic molecule.
- PIC polyion complex
- PIC polymer micelle examples include PEG-PAsp (DET) -Chol, PEG-PAsp (DET), PIC micelle formed by polymolecular association of PEG-PLys and mRNA, PAsp (TET), PAsp ( Those using another polycation such as TEP) as a block copolymer (Uchida, S., et al., Biomaterials (2016) 82, p.221-228) and those using a triblock copolymer (Osawa) , S., et al., Biomacromolecules 17, p354-361 (2016)).
- hybrid polymer micelles with inorganic particles examples include PEGylated calcium phosphate (CaP) particles (Pittela, et al., Biomaterials (2011) 32, p. 3106-3114), PEGylated silica particles (Miyata, K. et al. , Et al., Biomaterials (2010) 31, p4764-4770).
- CaP PEGylated calcium phosphate
- the lipidic mRNA carrier is formed using lipid or cationic lipid as a carrier, and the mRNA is in an encapsulated or bound form.
- lipid or cationic lipid for example, N- [1- (2,3-dioleyloxy) propyl] -N, N, N-trimethylammonium chloride (DOTMA), 2,3-dioleyloxy-N- [2- (sperminecarboxamide) Ethyl] -N, N-dimethyl-1-propanaminium trifluoroacetic acid (DOSPA), 1,2-dioleoyloxy-3- (trimethylammonium) propane (DOTAP), N- [1- (2,3 -Dimyristyloxy) propyl] -N, N-dimethyl-N- (2-hydroxyethyl) ammonium bromide (DMRIE) or DC-cholesterol; lipids such as distearoyl phosphatidylcholine (DSPC) or dio
- the cationic polymer complex is, for example, a mixture of linear or branched polyethyleneimine, polylysine, polyarginine, chitosan derivative, polymethacrylic acid derivative and mRNA.
- These transport carriers can be prepared by a known method or a method analogous thereto.
- RNA vaccines are not used with adjuvants. In some other embodiments, the RNA vaccine is used with an adjuvant. When used with an adjuvant, the RNA vaccine may be formulated with an adjuvant.
- An adjuvant is any compound suitable for enhancing an immune response. Such adjuvants are known, and those skilled in the art can select an appropriate one from any adjuvant.
- the mRNA vaccine can be used for prevention or treatment of the disease in a subject in need of prevention or treatment of the disease.
- diseases to be prevented or treated include cancer, viral infections, bacterial infections, fungal infections, protozoal infections, and autoimmune diseases.
- the disease can be prevented or treated.
- a “subject” is a human or non-human organism, such as avian and non-human mammals (eg, cows, monkeys, cats, mice, rats, guinea pigs, hamsters, pigs, dogs, rabbits, sheep, and horses). is there.
- avian and non-human mammals eg, cows, monkeys, cats, mice, rats, guinea pigs, hamsters, pigs, dogs, rabbits, sheep, and horses.
- the MRNA vaccine can be formulated according to a conventional method.
- the mRNA vaccine comprises a pharmaceutically acceptable additive.
- Pharmaceutically acceptable additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethylcellulose, sodium polyacrylate, sodium alginate, water-soluble dextran, Sodium carboxymethyl starch, pectin, methylcellulose, ethylcellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose And pharmaceutically acceptable surfactants.
- the above additives are selected from the above alone or in appropriate combination depending on the dosage form of the mRNA vaccine.
- a solvent for example, physiological saline, buffer solution, glucose solution, etc.
- Tween 80, Tween 20, gelatin, human serum albumin, etc. are added thereto.
- Tween 80, Tween 20, gelatin, human serum albumin, etc. are added thereto.
- it may be freeze-dried to obtain a dosage form that dissolves before use.
- Freeze-drying excipients include, for example, sugars such as mannitol, glucose, lactose, sucrose, mannitol, sorbitol, starch such as corn, wheat, rice, potato or other plant-derived starch, methylcellulose, hydroxypropylmethylcellulose or carboxy Examples thereof include cellulose such as sodium methylcellulose, rubber such as gum arabic and gum tragacanth, gelatin, collagen and the like.
- the dosage of the mRNA vaccine can be appropriately selected depending on the age, sex, symptom, administration route, administration frequency, dosage form, etc. of the subject.
- An effective dosage of an mRNA vaccine is the amount of vaccine that reduces the symptoms or condition of the disease.
- the therapeutic efficacy and toxicity of such mRNA vaccines is based on standard pharmaceutical procedures in cell cultures or laboratory animals such as ED50 (therapeutically effective dose in 50% of the population) and LD50 (in 50% of the population). The dose which is lethal to).
- the dosage of mRNA vaccine ranges from 10 ng to 1 g, 100 ng to 100 mg, 1 ⁇ g to 10 ⁇ g, or 30 ⁇ g to 300 ⁇ g of mRNA per day for an adult.
- the route of administration of the mRNA vaccine can be appropriately selected and includes, for example, transdermal, intranasal, transbronchial, intramuscular, intraperitoneal, intravenous, subcutaneous, rectal, and intravaginal routes.
- the route is not limited.
- the number of administrations of mRNA vaccine can be one time or multiple times as long as side effects are within the clinically acceptable range.
- antibody titer or cellular immune activity upon mRNA vaccine administration is measured.
- the antibody titer can be evaluated by collecting blood from a living body and quantifying IgG in serum.
- Cellular immune activity can be evaluated by isolating and culturing lymphocytes from a living body and measuring 3 H-thymidine incorporation.
- Kit The kit according to the second aspect of the present invention is characterized by comprising the mRNA vaccine.
- the kit can be preferably used, for example, in the method for treating various diseases using the RNA vaccine.
- the storage state of the mRNA vaccine is not limited, and a solution state or a powder state can be selected in consideration of its stability (storage property) and ease of use.
- the kit may contain other components other than the mRNA vaccine. Examples of other components include various buffers and instructions for use (use manual).
- the kit may or may not include an adjuvant. Preferably, the kit does not include an adjuvant.
- the specific mRNA vaccine of the second aspect of the present invention has a slightly reduced protein expression efficiency (“mRNA: pU” in FIG. 40), the translation activity is sufficiently maintained when the above double-stranded mRNA is used. ("1", “2", and “3” in FIG. 40). Furthermore, the intensity of the immune response could be adjusted by adjusting the number of RNA oligomers to hybridize (“1”, “2” and “3” in FIGS. 38 and 39). Excessive inflammation can cause side effects and may be undesirable for obtaining a vaccine effect. The fact that the intensity of the current immune response can be adjusted by changing the number of RNA oligomers is extremely important in obtaining an inflammatory reaction having an appropriate intensity for obtaining a vaccine effect.
- the mRNA vaccine of the third aspect of the present invention is easier to construct a blunt 5 ′ terminal triphosphorylated structure necessary for RIG-I recognition than the mRNA vaccine of the second aspect.
- the complementary RNA of the target RNA is transcribed as a by-product when preparing the second RNA strand by in vitro transcription, but the specific mRNA of the second aspect Compared to vaccines, the production of by-products can be easily avoided.
- a third aspect of the present invention comprises mRNA encoding an antigen, at least one first RNA oligomer hybridized to the mRNA, and a second RNA oligomer hybridized to the first RNA oligomer.
- a double-stranded RNA consisting of The first RNA oligomer is (A) a first RNA sequence consisting of a 12-40 base sequence complementary to the mRNA sequence and a second RNA sequence consisting of a 10-200 base sequence complementary to the second RNA oligomer sequence; An RNA sequence comprising in this order from the 5 ′ end, (B) 90% identity with a sequence of 12 to 40 bases complementary to the mRNA sequence and complementary to the sequence of the first RNA sequence and the second RNA oligomer that hybridize to the mRNA An RNA sequence comprising a second RNA sequence having at least 90% identity with a 10-200 base sequence and hybridizing to the second RNA oligomer in this order from the 5 ′ end, (C) a second RNA sequence consisting of a sequence of 10 to 200 bases complementary to the sequence of the second RNA oligomer, and a first RNA sequence consisting of a sequence of 12 to 40 bases complementary to the sequence of mRNA An RNA sequence comprising in this order from
- mRNA mRNA means messenger RNA and usually comprises a 5 ′ untranslated region (5′UTR), a coding region and a 3 ′ untranslated region (3′UTR).
- the mRNA usually further comprises a cap structure (5 ′ Cap) at the 5 ′ end and a poly A sequence at the 3 ′ end.
- the mRNA used for the mRNA vaccine may be any of the following.
- mRNA containing 5 ′ Cap, 5 ′ UTR, coding region, 3 ′ UTR, and poly A in this order (2) mRNA containing 5′Cap, 5′UTR, coding region, and poly A in this order. (3) mRNA containing 5′UTR, coding region, 3′UTR, and poly A in this order. (4) mRNA containing 5′UTR, coding region, and poly A in this order.
- RNA ⁇ / RTI> used for the mRNA vaccine can be prepared by transcription of a template DNA encoding a target gene in an in vitro environment by a known method. For example, it can be produced according to the method described in Blood 108 (13) (2006) 4009-17. Specifically, a template DNA in which a poly A / T chain is incorporated downstream of a protein coding sequence is cleaved immediately downstream of the poly A / T chain and placed in a buffer solution containing a translation enzyme, a nucleoside, and a 5 ′ cap analog. In vitro transcription is performed, and then mRNA is purified. A more specific method for preparing mRNA is as described in Examples below.
- the antigen encoded by the coding region of mRNA can be arbitrarily selected from known antigens suitable for inducing an immune response. More specifically, examples of the antigen include tumor antigens, virus-derived antigens, bacteria-derived antigens, fungal-derived antigens, protozoan-derived antigens, animal-derived antigens, plant-derived antigens, and autoimmune disease self-antigens.
- the antigen encoded by the mRNA may be one antigen, or two or more (eg, 2, 3, 4, or 5 or more) identical or different antigens. In some aspects of the third aspect of the invention, the antigen encoded by the mRNA is a single antigen.
- the length of the poly A sequence of mRNA is, for example, 10 to 500 bases, preferably 30 to 300 bases, and more preferably 60 to 250 bases.
- the 5'UTR and 3'UTR sequences of the mRNA may have 100% sequence identity with the naturally occurring sequence, or may be partially or wholly in other 5'UTR and / or 3'UTR sequences. It may be replaced with a sequence.
- Other 5 ′ UTR and / or 3 ′ UTR sequences include, for example, 5 ′ UTR and / or 3 ′ UTR sequences of mRNA encoding globin, hydrosteroid (17- ⁇ ) dehydrogenase 4, or albumin. .
- the mRNA is not modified. In this case, since the mRNA itself is natural, it can be expected that the translation process is hardly impaired.
- the mRNA is modified to further stabilize the mRNA.
- the modification of mRNA include chemical modification of the base of mRNA, modification of the G / C content of the coding region of mRNA, modification of the Cap structure of mRNA, and the like.
- the chemical modification of the base of mRNA is, for example, known to improve the enzyme resistance of mRNA.
- Such chemically modified bases of mRNA itself include, for example, methylated bases (eg, 5-methylcytosine), sulfur modified bases (eg, 2-thiouridine), pseudouridine, N1 methyl pseudouridine, and 5-methoxyuridine. It is done.
- the modification of the G / C content of the coding region of mRNA is to modify the content of G (guanine) / C (cytosine) so that more stable mRNA can be obtained.
- the modification of the cap structure of mRNA is that the 2nd position of the first or second ribose on the 5 'side is a methoxy group, thereby improving the expression efficiency.
- MRNA can be prepared and modified by a known method or a method analogous thereto.
- RNA oligomer In the third aspect of the invention, at least one first RNA oligomer hybridizes to mRNA. Furthermore, the second RNA oligomer is hybridized to the first RNA oligomer.
- the first RNA oligomer is (A) a first RNA sequence consisting of a 12-40 base sequence complementary to the mRNA sequence and a second RNA sequence consisting of a 10-200 base sequence complementary to the second RNA oligomer sequence; An RNA sequence comprising in this order from the 5 ′ end, (B) 90% identity with a sequence of 12 to 40 bases complementary to the mRNA sequence and complementary to the sequence of the first RNA sequence and the second RNA oligomer that hybridize to the mRNA An RNA sequence comprising a second RNA sequence having at least 90% identity with a 10-200 base sequence and hybridizing to the second RNA oligomer in this order from the 5 ′ end, (C) a second RNA sequence consisting of a sequence of 10 to 200 bases complementary to the sequence of the second RNA oligomer, and a first RNA sequence consisting of a sequence of 12 to 40 bases complementary to the sequence of mRNA An RNA sequence comprising in this order from the 5 ′ end, or (d)
- RNA sequence having 90% or more identity is, for example, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, It is 99.7% or more, 99.8% or more, or 99.9% or more.
- identity of the RNA sequence can be determined using an analysis program such as BLAST (see, for example, Altzshul SF et al., J. Mol. Biol. 215, 403 (1990)). When using BLAST, the default parameters of each program are used.
- Hybridizes to mRNA means that an RNA oligomer hybridizes to mRNA under the hybridization conditions described below. “Hybridizes to the first RNA” means that the second RNA oligomer hybridizes to the first RNA under the hybridization conditions described later.
- the first RNA sequence of the first RNA oligomer is designed to hybridize to a sequence of 12 to 40 bases of mRNA.
- the first RNA sequence of the first RNA oligomer consists of a 12-30 base sequence complementary to the mRNA sequence. More preferably, the first RNA sequence of the first RNA oligomer consists of a sequence of 15 to 23 bases complementary to the sequence of mRNA. More preferably, the first RNA sequence of the first RNA oligomer sequence is a 17-base sequence complementary to the mRNA sequence.
- the position in the mRNA to which the RNA oligomer is hybridized may be any position of 5'UTR, coding region, 3'UTR, and poly A sequence. It is desirable that the RNA oligomer is designed so that the secondary structure of the mRNA is predicted and the mRNA chain is hybridized to a portion having no secondary structure. That is, the RNA oligomer is preferably designed so as to hybridize to a portion having no secondary structure in the entire mRNA sequence. Examples of the software for predicting the secondary structure of mRNA include those described in the examples described later. In some aspects, the RNA oligomer is designed to hybridize to at least one sequence of the 5'UTR, coding region and 3'UTR of the mRNA.
- the second RNA sequence of the first RNA oligomer is hybridized with a sequence of 10 to 200 bases of the second RNA oligomer in addition to the first RNA sequence having the respective base lengths. Designed. In some embodiments, the second RNA sequence of the first RNA oligomer is 15-150 complementary to the sequence of the second RNA oligomer in addition to the first RNA sequence being each base length. Consists of a base sequence. More preferably, the second RNA sequence of the first RNA oligomer has 20 to 100 bases complementary to the sequence of the second RNA oligomer in addition to the first RNA sequence having the base length. It consists of an array. More preferably, the second RNA sequence of the sequence of the first RNA oligomer is 20 to 80 complementary to the sequence of the second RNA oligomer in addition to the first RNA sequence having the respective base lengths. It consists of a base sequence.
- the second RNA sequence of the first RNA oligomer is designed as follows. That is, it is designed to satisfy at least one of the following (i) to (iv), more preferably to satisfy two, three, or four. In some preferred embodiments, the second RNA sequence of the first RNA oligomer satisfies at least the following (i) and (ii), more preferably the following (iii) and (iv): Design to satisfy at least one.
- RNA oligomer When preparing a second RNA oligomer containing 5′-terminal triphosphorylation by transcription of template DNA in an in vitro environment, a complementary strand RNA (byproduct) to the target RNA oligomer should not be formed.
- the end of the double-stranded RNA on the side where the second RNA oligomer is hybridized to the first RNA oligomer has a 5 ′ end triphosphorylated structure, preferably a smooth 5 ′ end triphosphorylated structure.
- the second RNA sequence and the second RNA oligomer do not hybridize to the sequence on the mRNA, and (iv) the first and second RNA oligomers do not form secondary structures.
- RNA oligomer containing 5′-terminal triphosphorylation by transcription of template DNA in an in vitro environment complementary strand RNA (by-product) to the target RNA oligomer is not formed.
- the following design is performed. That is, a second RNA oligomer is prepared by removing a base necessary for transcription of complementary RNA. Therefore, the template DNA is designed so that the target second RNA oligomer is transcribed even if the base is removed.
- the sequence GUGUGUGUGU (SEQ ID NO: 67) is transcribed in vitro
- the sequence ACACACACAC (SEQ ID NO: 68) can be generated as a by-product, but the generation of this by-product is avoided by in vitro transcription except A.
- the second RNA sequence of the first RNA oligomer is designed so that such a second RNA oligomer can be prepared.
- the end of the double-stranded RNA on the side where the second RNA oligomer is hybridized to the first RNA oligomer has a 5′-end triphosphorylated structure, preferably a smooth 5′-end triphosphorylated structure.
- design as follows. That is, when the first RNA oligomer is the RNA sequence (a) or the RNA sequence (b), the second RNA oligomer having a triphosphorylated structure at the 5 ′ end is transcribed in vitro. 2 oligomers are prepared.
- the first oligomer is prepared so as to have a blunt end when the 5 ′ end of the second oligomer and the 3 ′ end of the first oligomer are hybridized. Then, a second RNA sequence of the first RNA oligomer is designed so that such first and second RNA oligomers can be prepared.
- the first RNA oligomer is the RNA sequence (c) or the RNA sequence (d)
- the first RNA oligomer is prepared by in vitro transcription of the first RNA oligomer.
- the second oligomer is prepared so as to have a blunt end when the 5 ′ end of the first RNA oligomer and the 3 ′ end of the second RNA oligomer are hybridized. Then, a second RNA sequence of the first RNA oligomer is designed so that such first and second RNA oligomers can be prepared.
- the secondary structure after the design is predicted as the secondary structure of a plurality of RNA strands. It verifies with software (NUPACK, http://www.nupack.org) etc. which can be performed.
- the secondary structure after the design is software (NUPACK, (http://www.nupack.org) etc.
- a linker sequence may or may not be included between the first RNA sequence and the second RNA sequence of the first RNA oligomer.
- a linker sequence is included.
- the base length of the linker sequence is preferably 1 to 100 bases, more preferably 2 to 30 bases in addition to the base lengths of the first RNA sequence and the second RNA sequence, Preferably it is 2 to 20 bases.
- the linker sequence is designed so as not to hybridize with other sites of mRNA or RNA oligomer, or to be difficult to hybridize.
- a linker using adenine (A) or uracil (U) is designed so that the linker sequence is difficult to hybridize to mRNA.
- the linker sequence is an oligoadenine sequence having the base length.
- the mRNA corresponding to the position of the linker sequence is uracil (U)
- it will be hybridized to the mRNA if the base at that position is adenine (A).
- the base at that position is preferably changed to uracil (U).
- the first RNA oligomer may further include other sequences, or may not include other sequences. In some embodiments, other sequences are included.
- the “other sequence” is, for example, a promoter sequence, a restriction enzyme sequence, a sequence remaining unavoidable when designing an RNA oligomer, or a part thereof.
- the base length of “other sequence” is, for example, 1 to 30 bases, preferably 1 to 25 bases, and more preferably 1 to 2 bases.
- the second RNA oligomer includes a sequence of, for example, 10 to 200 bases that hybridizes to the second RNA sequence of the first RNA oligomer, preferably includes a sequence of 15 to 150 bases, and more preferably includes 20 to 100 bases. And more preferably a 24 base sequence.
- the method for designing the second RNA oligomer is as described for the second RNA sequence of the first RNA oligomer.
- the second RNA oligomer may further contain other sequences, or may not contain other sequences.
- the “other sequence” is, for example, a promoter sequence, a restriction enzyme sequence, a sequence remaining unavoidable when designing an RNA oligomer, or a part thereof.
- the base length of “other sequence” is, for example, 1 to 30 bases, preferably 1 to 25 bases, and more preferably 1 to 2 bases.
- the first and second RNA oligomers are those that do not contain chemical modifications. In some other embodiments, the first and second RNA oligomers comprise chemical modifications. Examples of the chemical modification include modification with a hydrophobic group. Examples of the modification with a hydrophobic group include cholesterol modification and tocopherol modification. Examples of the chemical modification include polyethylene glycol modification. The definition of “chemical modification” does not include the 5′-terminal triphosphate structure.
- the first and second RNA oligomers can be prepared by a known method or a method analogous thereto. Specifically, the first and second RNA oligomers are produced, for example, from template DNA by in vitro transcription. In principle, the preparation of the first and second RNA oligomers can be carried out in substantially the same manner as the preparation of mRNA described above, whereas mRNA has a 5 ′ cap analog added during transcription. The first and second RNA oligomers are prepared without adding a cap analog. When the first and second RNA oligomers are thus biologically prepared, they can have a triphosphate structure at the 5 'end. The method for removing triphosphoric acid is as described later. The RNA oligomer having no triphosphate structure at the 5 'end can be chemically synthesized.
- Double stranded RNA is obtained by hybridizing at least one of the aforementioned first RNA oligomers to the aforementioned mRNA and hybridizing the second RNA oligomer to the first RNA oligomer. Moreover, what consists of a 1st RNA oligomer and the 2nd RNA oligomer hybridized to the 1st RNA oligomer may be called "double stranded RNA oligomer.”
- Double-stranded RNA can be prepared by hybridization of mRNA and first RNA oligomer, and hybridization of first RNA oligomer and second RNA oligomer. More specifically, the hybridization can be performed under the conditions described in Examples described later or conditions equivalent thereto.
- the number of the first RNA oligomers to be hybridized to one mRNA is at least 1, preferably 1 to 50, more preferably 1 to 15, and further preferably 1 to 5. is there. If the number of first RNA oligomers is in the range of 1-50, the translation efficiency of mRNA can be maintained at a relatively high level. Further, when the number of double-stranded RNA oligomers composed of the first RNA oligomer and the second RNA oligomer to be hybridized with one mRNA increases, the immunostimulatory action is improved. Therefore, the immune reaction can be controlled by adjusting the number of double-stranded RNA oligomers composed of the first RNA oligomer and the second RNA oligomer hybridized to one mRNA. Thus, here, a method for regulating an immune response is provided, which comprises regulating the number of double-stranded RNA oligomers that are hybridized to one mRNA.
- the number of second RNA oligomers to be hybridized to one first RNA oligomer is one.
- Hybridization of RNA oligomers to mRNA can be performed by known methods and conditions. More specifically, in hybridization, the temperature is gradually lowered after heating and allowing to stand for a certain period of time. Heating is performed for the purpose of binding mRNA and oligomer more efficiently by releasing complementary bonds existing in and between mRNA and oligomer molecules. If proper hybridization is ensured, the temperature time can be appropriately adjusted. In particular, poly A and poly U are unlikely to be combined with other sequences in advance, and more gentle heating conditions can be set. The slower the temperature drop, the more specific the hybridization. Further, the oligomer chain length does not greatly affect the setting of hybridization conditions. Conditions should be set as appropriate while evaluating the hybridization efficiency. For example, the methods and conditions described in the examples described later can be mentioned.
- the double stranded RNA has a triphosphate structure at the 5 'end of the RNA oligomer.
- a triphosphate structure at the 5 'end of the RNA oligomer By having a triphosphate structure at the 5 'end of the RNA oligomer, a stronger inflammatory reaction can be induced.
- the double-stranded RNA does not have a triphosphate structure at the 5 'end of the RNA oligomer.
- the method for removing triphosphorylation can be carried out by a known method or a method analogous thereto.
- a method for removing triphosphorylation for example, a method using an artificial phosphatase (New England Biolabs, cat. No. M0289S) as in Examples described later can be mentioned.
- the double-stranded RNA has a blunt end at the end where the second RNA oligomer is hybridized to the first RNA oligomer. It is known that immunity induction via RIG-I is improved when a triphosphorylated structure is present at the blunt end 5 '.
- RNA containing 5'-terminal triphosphorylation is transcribed by in vitro transcription, it is designed so that complementary strand RNA to the target RNA is not formed.
- RNA is prepared by removing a base necessary for transcription of complementary strand RNA. Therefore, even if the base is removed, it is designed so that the target RNA is transcribed.
- sequence GUGUGUGUGU (SEQ ID NO: 67) is transcribed in vitro
- sequence ACACACACAC (SEQ ID NO: 68) can be generated as a by-product, but the generation of this by-product is avoided by in vitro transcription except A.
- the double stranded RNA is in naked form. That is, double-stranded RNA is not accompanied by a transport carrier. In some other embodiments, the double-stranded RNA is in a form encapsulated in a transport carrier.
- the transport carrier is not particularly limited as long as it can enclose the double-stranded mRNA and deliver it to a suitable site in the body of the subject.
- the transport carrier is a lipidic mRNA carrier or a cationic polymer complex, more preferably a polymeric micelle or a lipidic mRNA carrier.
- the polymer micelle has a two-layer structure of an inner core formed of condensed nucleic acid and a cationic polymer and an outer shell formed of a hydrophilic polymer.
- the cationic polymer is, for example, a polyamino acid derivative.
- the hydrophilic polymer is, for example, polyethylene glycol (“PEG”).
- the inner core physically or chemically encapsulates the mRNA.
- the outer shell delivers mRNA encapsulated in the inner shell to a predetermined tissue due to its physicochemical properties.
- Polymeric micelles can enter cells by endocytosis.
- the polymer micelle can use, for example, a combined action of a polycation and a nucleic acid (polyion complex (“PIC”)) on a block polymer, or a hybrid micelle of the polymer and an inorganic molecule.
- PIC polymer micelle examples include PEG-PAsp (DET) -Chol, PEG-PAsp (DET), PIC micelle formed by polymolecular association of PEG-PLys and mRNA, PAsp (TET), PAsp ( Those using another polycation such as TEP) as a block copolymer (Uchida, S., et al., Biomaterials (2016) 82, p.
- hybrid polymer micelles with inorganic particles include PEGylated calcium phosphate (CaP) particles (Pittela, et al., Biomaterials (2011) 32, p. 3106-3114), PEGylated silica particles (Miyata, K. et al. , Et al., Biomaterials (2010) 31, p4764-4770).
- CaP PEGylated calcium phosphate
- the lipidic mRNA carrier is formed using lipid or cationic lipid as a carrier, and the mRNA is in an encapsulated or bound form.
- lipid or cationic lipid for example, N- [1- (2,3-dioleyloxy) propyl] -N, N, N-trimethylammonium chloride (DOTMA), 2,3-dioleyloxy-N- [2- (sperminecarboxamide) Ethyl] -N, N-dimethyl-1-propanaminium trifluoroacetic acid (DOSPA), 1,2-dioleoyloxy-3- (trimethylammonium) propane (DOTAP), N- [1- (2,3 -Dimyristyloxy) propyl] -N, N-dimethyl-N- (2-hydroxyethyl) ammonium bromide (DMRIE) or DC-cholesterol; lipids such as distearoyl phosphatidylcholine (DSPC) or dio
- the cationic polymer complex is, for example, a mixture of linear or branched polyethyleneimine, polylysine, polyarginine, chitosan derivative, polymethacrylic acid derivative and mRNA.
- These transport carriers can be prepared by a known method or a method analogous thereto.
- RNA vaccines are not used with adjuvants. In some other embodiments, the RNA vaccine is used with an adjuvant. When used with an adjuvant, the RNA vaccine may be formulated with an adjuvant.
- An adjuvant is any compound suitable for enhancing an immune response. Such adjuvants are known, and those skilled in the art can select an appropriate one from any adjuvant.
- the mRNA vaccine can be used for prevention or treatment of the disease in a subject in need of prevention or treatment of the disease.
- Diseases to be prevented or treated can include, for example, cancer, viral infections, bacterial infections, fungal infections, protozoal infections, and autoimmune diseases.
- the disease can be prevented or treated.
- a “subject” is a human or non-human organism, such as avian and non-human mammals (eg, cows, monkeys, cats, mice, rats, guinea pigs, hamsters, pigs, dogs, rabbits, sheep, and horses). is there.
- avian and non-human mammals eg, cows, monkeys, cats, mice, rats, guinea pigs, hamsters, pigs, dogs, rabbits, sheep, and horses.
- the MRNA vaccine can be formulated according to a conventional method.
- the mRNA vaccine comprises a pharmaceutically acceptable additive.
- Pharmaceutically acceptable additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethylcellulose, sodium polyacrylate, sodium alginate, water-soluble dextran, Sodium carboxymethyl starch, pectin, methylcellulose, ethylcellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose And pharmaceutically acceptable surfactants.
- the above additives are selected from the above alone or in appropriate combination depending on the dosage form of the mRNA vaccine.
- a solvent for example, physiological saline, buffer solution, glucose solution, etc.
- Tween 80, Tween 20, gelatin, human serum albumin, etc. are added thereto.
- Tween 80, Tween 20, gelatin, human serum albumin, etc. are added thereto.
- it may be freeze-dried to obtain a dosage form that dissolves before use.
- Freeze-drying excipients include, for example, sugars such as mannitol, glucose, lactose, sucrose, mannitol, sorbitol, starch such as corn, wheat, rice, potato or other plant-derived starch, methylcellulose, hydroxypropylmethylcellulose or carboxy Examples thereof include cellulose such as sodium methylcellulose, rubber such as gum arabic and gum tragacanth, gelatin, collagen and the like.
- the dosage of the mRNA vaccine can be appropriately selected depending on the age, sex, symptom, administration route, administration frequency, dosage form, etc. of the subject.
- An effective dosage of an mRNA vaccine is the amount of vaccine that reduces the symptoms or condition of the disease.
- the therapeutic efficacy and toxicity of such mRNA vaccines is based on standard pharmaceutical procedures in cell cultures or laboratory animals such as ED50 (therapeutically effective dose in 50% of the population) and LD50 (in 50% of the population). The dose which is lethal to).
- the dosage of mRNA vaccine ranges from 10 ng to 1 g, 100 ng to 100 mg, 1 ⁇ g to 10 ⁇ g, or 30 ⁇ g to 300 ⁇ g of mRNA per day for an adult.
- the route of administration of the mRNA vaccine can be appropriately selected and includes, for example, transdermal, intranasal, transbronchial, intramuscular, intraperitoneal, intravenous, subcutaneous, rectal, and intravaginal routes.
- the route is not limited.
- the number of administrations of mRNA vaccine can be one time or multiple times as long as side effects are within the clinically acceptable range.
- antibody titer or cellular immune activity upon mRNA vaccine administration is measured.
- the antibody titer can be evaluated by collecting blood from a living body and quantifying IgG in serum.
- Cellular immune activity can be evaluated by isolating and culturing lymphocytes from a living body and measuring 3 H-thymidine incorporation.
- Kit The kit according to the third aspect of the present invention is characterized by comprising the mRNA vaccine.
- the kit can be preferably used, for example, in the method for treating various diseases using the RNA vaccine.
- the storage state of the mRNA vaccine is not limited, and a solution state or a powder state can be selected in consideration of its stability (storage property) and ease of use.
- the kit may contain other components other than the mRNA vaccine. Examples of other components include various buffers and instructions for use (use manual).
- the kit may or may not include an adjuvant. Preferably, the kit does not include an adjuvant.
- Example 1-1 Synthesis of various block copolymers 1.1. Synthesis of PEG-PAsp (DET) -Chol PEG-PAsp (DET) -Chol was synthesized according to a report (Oba, M., et al., Biomaterials (2011) 32, p. 652-663) (Scheme 1). The synthesis scheme is as follows.
- NCA- ⁇ -benzyl-L-aspartate-N-carboxylic acid anhydride
- M w of PEG: 12 kDa ⁇ -methoxy- ⁇ -amino-polyethylene glycol
- PEG-PBLA PEG-poly ( ⁇ -benzyl L-aspartate)
- a cholesterol group was introduced into the ⁇ -terminal of the synthesized PEG-PBLA.
- Cholesterol chloroform (328 mg) dissolved in 11 v / v% triethylamine (TEA) / DCM mixed solution (200 ⁇ L) was slowly added to PEG-PBLA (200 mg) dissolved in DCM (4 mL) and stirred at room temperature for 24 hours. did.
- the reaction solution was reprecipitated in diethyl ether, and PEG-PBLA-Cholesterol (Chol) was recovered.
- PEG-PAsp (DET) -Chol was synthesized by aminolysis reaction of the collected PEG-PBLA-Chol.
- PEG-PBLA-Chol 100 mg was dissolved in benzene, freeze-dried, and dried PEG-PBLA-Chol and Dry diethylenetriamine (DET) (50 equivalents to PBLA) in 0.5 M thiourea N-methyl- Dissolved in 2-pyrrolidone (NMP). These solutions were cooled to 10 ° C., and the PEG-PBLA-Chol solution was slowly added dropwise to the DET solution and stirred for 1 hour. After the reaction, the reaction solution was neutralized with 5N HCl aqueous solution while keeping the solution temperature at 10 ° C.
- Example 1-2 Preparation of mRNA mRNA is prepared from template DNA by in vitro transcription, and the template DNA was prepared as follows. First, T7-Gluc plasmid inserts the Gluc coding sequence (FIG. 15 and SEQ ID NO: 32) from pCMV-Gluc control plasmid (New England BioLabs, Ipswich, MA, USA) into the HindIII of the pSP73 vector (Promega), Xba1 site. It was produced by. Thereafter, T7-Gluc poly A120 plasmid was prepared by inserting A120- (BsmBI cleavage site) into the EcoR1-Bgl2 site of T7-Gluc plasmid. Then, after cutting with BsmBI, end blunting was performed with T4 DNA Polymerase (Takara Bio), and used for the following in vitro transcription.
- T7-Gluc plasmid inserts the Gluc coding sequence (FIG. 15 and SEQ ID NO: 32) from
- the mRNA was subjected to the above restriction enzyme treatment encoding Gaussia luciferase (Gluc) using mMESSAGE mMACHINE (trade name) T7 (Thermo Fisher Scientific), and the smoothed template DNA (T7-Gluc poly A120 plasmid) was stored in the mRNA. It was prepared by transferring in a vitro environment. The transcribed mRNA was purified and recovered using RNeasy Mini Kit (QIAGEN). The recovered mRNA concentration was measured by NanoDrop (Thermo Fisher Scientific). In addition, it was confirmed that the target mRNA was prepared by electrophoresis using an Agilent 2100 bioanalyzer (Agilent technologies).
- Agilent 2100 bioanalyzer Agilent 2100 bioanalyzer
- NanoDrop confirmed the production of high-purity mRNA having an absorbance ratio of 260 to 280 nm of 2.0 to 2.2 at a high concentration of 500 to 1,000 ng / ⁇ L.
- bioanalyzer analysis confirmed the production of mRNA of the intended size.
- the sequence of the prepared mRNA is shown in FIG. In the sequence of FIG. 14, the underlined portion is an open reading frame (ORF), the upstream of the ORF is 5′UTR (54 bases), the downstream of the ORF is 3′UTR (52 bases), and further downstream 120A is a poly A array.
- ORF open reading frame
- the upstream of the ORF is 5′UTR (54 bases)
- the downstream of the ORF is 3′UTR (52 bases)
- further downstream 120A is a poly A array.
- the number of Poly A is theoretically incorporated into the template DNA at 120 bp, and the mRNA is 119 bases. However, the number can be increased or decreased at the stage of DNA amplification or mRNA preparation.
- RNA Oligomer Hybridization RNA oligomers were designed and prepared as follows.
- RNA secondary structure prediction software http://rtips.dna.bio.keio.ac.jp/ipknot/) predicts the secondary structure of Gluc mRNA, and the RNA strand has no secondary structure RNA oligomers were designed.
- the RNA oligomer was requested and synthesized at Hokkaido System Science, including cholesterol modification at the 5 ′ end or 3 ′ end.
- sequence of the following RNA oligomer shows an overhang sequence.
- Mismatched Chol-RNA oligo is a 19-mer Chol-modified poly A that does not hybridize to mRNA.
- “Chol-overhang” indicates that the 5 ′ end of the RNA oligomer is cholesterol-modified
- RNA oligomer 17mer (1) (SEQ ID NO: 2): UCUUUGAGCACCUCCCAG 17mer (2) (SEQ ID NO: 3): CUCUAGAUGCAUUGCUCG 17mer (3) (SEQ ID NO: 4): CUCGGCCCACAGCGAUGC 17mer (4) (SEQ ID NO: 5): GCGGCAGCCCAUUCUUG 17mer (5) (SEQ ID NO: 6): AUCUCAGGAAUGUCGAC
- overhang 2base (1) (SEQ ID NO: 10): AA UCUUUGAGCACCUCCCAG
- Mismatch Chol-RNA oligo (SEQ ID NO: 24): AAAAAAAAAAAAAAAAAAAAA
- Hybridization was performed by heating 1 equivalent of an RNA oligomer (overhang 2base (1)) to mRNA at 65 ° C. for 5 minutes and cooling to 30 ° C. over 10 minutes.
- the prepared RNA oligomer-modified mRNA was evaluated by polyacrylamide gel electrophoresis. A glycerol solution was added to an mRNA solution (1 ⁇ TBE buffer) so that the final concentration was 5 wt%, and electrophoresis was performed under conditions of 100 V, 800 mA, 200 W, and 30 min.
- FIG. 1 (2) and (3) electrophoresis was performed for RNA oligomers (overhang C 2base (1)) not subjected to Chol modification and unhybridized mRNA, respectively.
- FIG. 1 (1) only 1/16 of the amount of RNA oligomer (overhangh2base (1)) hybridized in FIG. 1 (2) was electrophoresed. If hybridization did not occur in FIG. 1 (2), a band derived from an RNA oligomer should be seen at the same position as in FIG. 1 (1), but almost no band was actually seen. That is, it was confirmed that the majority of RNA oligomers were hybridized.
- Example 1-4 Evaluation of mRNA expression ability in cultured cells and cell-free system
- RAW264.7 cells were seeded on a 12-well plate so as to give 300,000 cells / well, and 10 v / v%. Incubation was carried out in Dulbecco's Modified Eagle Medium (DMEM) containing fetal bovine serum (FBS) for 24 h. After incubation, DMEM was replaced with Opti-MEM (trade name) (Thermo Fisher Scientific), and Gluc mRNA prepared in Example 1-2 or RNA oligomer prepared in Example 1-3 (17mer (1), 23mer, 40mer).
- DMEM Dulbecco's Modified Eagle Medium
- FBS fetal bovine serum
- a complex consisting of Lipofectamine (trade name) LTX (Thermo Fisher Scientific) and mRNA was added so that the Gluc mRNA hybridized with 60 mer) was 1 ⁇ g / well. Four hours after transfection, the medium was collected, and the amount of Gluc contained therein was evaluated with a luminometer.
- Lipofectamine trade name
- LTX Thermo Fisher Scientific
- the mRNA prepared in Example 1-2 or the RNA oligomer prepared in Example 1-3 (17mer (1), 23mer, 40mer or the like) using Rabbit Reticulocyte Lysate System (Promega)
- the expression ability of Gluc mRNA hybridized with 60mer was evaluated.
- a mixed solution containing mRNA was prepared according to the protocol, and then incubated at 30 ° C. for 90 minutes.
- the expressed Gluc was evaluated by measuring the luminescence intensity using a luminometer.
- FIG. 2 (A) the efficiency of introducing mRNA into cultured cells was examined.
- an oligomer having a chain length of 23 mer or longer was hybridized (23 mer, 40 mer, 60 mer), unhybridized mRNA was used.
- the expression level of Gluc was significantly reduced as compared with the case (oligo ( ⁇ )).
- the expression level when the 17-mer oligomer was modified was almost the same as that when mRNA not hybridized was used.
- FIG. 2 (B) the protein translation efficiency in the cell-free system was constant regardless of the chain length of the RNA oligomer, and was almost the same as that of unhybridized mRNA.
- the chain length of the RNA oligomer is desirably 12 to 40 mer.
- Example 1-5 Preparation of mRNA-encapsulated PMs
- Gluc mRNA prepared in Example 1-2 or RNA oligomer (overhang 2base (1) or Chol-overhang 2base (1)) prepared in Example 1-3 was used.
- Hybridized Gluc mRNA was used.
- PEG-PAsp (DET) -Chol and Gluc mRNA were independently dissolved in 10 mM HEPES buffer (pH 7.4).
- the concentration of PEG-PAsp (DET) -Chol is 1.5 ((number of positive charges of PAsp (DET)) / (number of negative charges of mRNA)) (N + / P ⁇ ratio) at pH 7.4. Adjusted as follows.
- PEG-PAsp (DET) -Chol solution was added to the mRNA solution so that the final mRNA concentration was 33.3 ⁇ g / mL to prepare polymer micelles (PMs).
- the particle size and polydispersity of PMs were evaluated by Zetasizer Nano (Malvern Instruments). Moreover, PMs prepared using a transmission electron microscope (TEM) were observed. PMs consisting of PEG-PAsp (DET) were prepared in the same manner. The results are shown in Tables 1 and 2 and FIG.
- Example 1-6 Enzyme resistance test in serum
- Gluc mRNA prepared in Example 1-2 or Gluc mRNA hybridized with the following RNA oligomer prepared in Example 1-3 was used.
- RNA oligomer used in the experiments of FIGS. 4 (A) and 4 (B) Chol-overhang 0 (1) Chol-overhang 2base (1) Chol-overhang 5base (1) Mismatch Chol-RNA oligo
- RNA oligomer used in the experiments of FIGS. 4 (C) and (D) Chol-overhang 0 (2) Chol-overhang 2base (2) Chol-overhang 5base (2) Mismatch Chol-RNA oligo
- Fetal bovine serum was diluted with 10 mM HEPES buffer (pH 7.4) to a predetermined concentration, PM solution was added thereto, and the mixture was allowed to stand at 37 ° C. for 15 minutes. Then, RNA was extracted from the solution using RNeasy Mini Kit (QIAGEN). The extracted RNA was reverse transcribed into complementary DNA (cDNA), and the remaining cDNA was quantitatively evaluated by qRT-PCR. Relative values are shown with the amount of mRNA in the presence of FBS not standing at 37 ° C. as 100%.
- FIG. 4 (A) when PEG-PAsp (DET) -Chol was used, significant serum was obtained in the group hybridized with the oligomer having a 2-base overhang compared to the group not hybridized. An improvement in stability was observed. In addition, when there was no overhang, although the tendency for stability to improve was seen, the significant difference was not obtained. In the case of 5base, no stabilizing effect was observed. On the other hand, when PEG-PAsp (DET) was used, stability was improved when there was no overhang and when there was a 2base overhang (FIG. 4B). The above data were also reproduced when another oligo with a different hybridization location was used (FIG.
- the mismatched chol-RNA oligo was prepared by mixing PM with 19-mer Chol-modified poly A that does not hybridize with mRNA, but in this case, the enzyme resistance in serum was not improved, It was shown that it is necessary to hybridize to obtain the effect.
- Example 1-7 Agarose gel electrophoresis
- Gluc mRNA prepared in Example 1-2 or Gluc mRNA hybridized with RNA oligomer (Chol-overhang 2base (1)) prepared in Example 1-3 is used. It was.
- Tris 40 mM, acetic acid 20 mM, ethylenediaminetetraacetic acid (EDTA) 2Na 1 mM was prepared in 1 ⁇ TAE buffer (Tris-acetic acid-EDTA buffer) and adjusted to pH 7.4 using an aqueous sodium hydroxide solution.
- a buffer for electrophoresis was used.
- a 0.9 wt% agarose gel was prepared, and 5 ⁇ L of dextran sulfate and 5 ⁇ L of a 750 mM NaCl solution corresponding to the A / P ratio (number of negative charges of polyanion / number of phosphate groups of mRNA) were added to 15 ⁇ L of PM solution, and then 37 ° C. And incubated for 1 hour. After incubation, 2.5 ⁇ L of loading buffer was added and electrophoresis was performed at 100 V for 60 minutes to confirm the presence or absence of mRNA release.
- FIG. 5A to 5D the naked mRNA is placed in the leftmost column.
- mRNA is released from the micelle, a band is seen at the same position as the naked mRNA.
- the chol-modified oligomer is not hybridized, that is, when PEG-PAsp (DET) -Chol of FIG. 5 (A) is used and when PEG-PAsp (DET) of FIG. 5 (C) is used
- the release of a large amount of mRNA from micelles was observed at an A / P ratio of 1.5 to 2.
- Chol-modified oligomers were hybridized, no mRNA was observed even when any polymer was used, even at an A / P ratio of 2 (FIGS. 5B and 5D).
- Example 1-8 Enzyme resistance test in serum when the number of hybridizing oligos was increased
- Gluc mRNA prepared in Example 1-2 or the following prepared in Example 1-3 Gluc mRNA hybridized with RNA oligomers was used.
- Chol-overhang 2base (1) Chol-overhang 2base (2) Chol-overhang 2base (3) Chol-overhang 2base (4) Chol-overhang 2base (5)
- Example 1-9 PMs Luciferase Expression Test
- Gluc mRNA prepared in Example 1-2 or Gluc mRNA hybridized with the following RNA oligomer prepared in Example 1-3 was used.
- Chol-overhang 2base (1) Chol-overhang 2base (2) Chol-overhang 2base (3) Chol-overhang 2base (4) Chol-overhang 2base (5) 17mer (1)
- Each PMs was prepared using PEG-PAsp (DET) -Chol under the same conditions as in Example 5.
- Huh-7 cells (5,000 cells-well) were seeded on 96-well plates and incubated in DMEM (100 ⁇ L) containing 10 v / v% FBS for 24 hours. After the medium was replaced with a new one containing 10 v / v% FBS, 7.5 ⁇ L of PMs solution containing 250 ng mRNA was added. After incubation for 24 hours, 10 ⁇ L of the DMEM supernatant was collected, and the luminescence intensity of Gluc was measured using a luminometer.
- Example 1-10 Comparison of Chol modified to 5 ′ side and 3 ′ side
- Gluc mRNA prepared in Example 1-2 the following RNA oligomer prepared in Example 1-3 was used, or Gluc mRNA designed in the same place and hybridized with an oligomer having the following sequence having a 2base overhang sequence on the 3 ′ side was used.
- Each PMs was prepared using PEG-PAsp (DET) -Chol under the same conditions as in Example 5.
- a serum resistance test was performed in the same manner as in Example 1-8, PM was introduced into HuH-7 cells in the same manner as in Example 1-9, and the expression level of Gluc was evaluated.
- the result of the serum resistance test is shown in FIG. 8 (A), and the result of the expression level of Gluc is shown in FIG. 8 (B). In any evaluation, no significant difference was observed between the modification position of Chol at 3 ′ and 5 ′.
- Example 1-11 Evaluation of translation efficiency from Chol-modified mRNA in a cell-free system
- Gluc mRNA prepared in Example 1-2 or the following RNA oligomer prepared in Example 1-3 was hybridized. mRNA was used.
- Chol-overhang 2base (1) Chol-overhang 2base (2) Chol-overhang 2base (3) Chol-overhang 2base (4) Chol-overhang 2base (5)
- mRNA was not included in PM but used alone.
- the expression ability of mRNA modified with the Chol-RNA oligomer was evaluated using Rabbit Reticulocyte Lysate System (Promega). A mixed solution containing mRNA was prepared according to the protocol, and then incubated at 30 ° C. for 90 minutes. The expressed Gluc was evaluated by measuring the luminescence intensity using a luminometer.
- Chol-overhang 2base (1) was used in an experiment with one Chol-RNA oligomer.
- chol-overhang 2base (1) and (3) were used.
- chol-overhang 2base (1) to (3) was used.
- chol-overhang 2base (1) to (4) was used.
- chol-overhang 2base (1) to (5) was used.
- Example 1-12 Influence on Endogenous Gene Expression
- the following RNA oligos designed and prepared in the same manner as in Example 1-3 or the following siRNAs prepared as described below were used.
- “Chol-” indicates that the 5 ′ end of the RNA oligomer is cholesterol-modified.
- RNA oligomer sequence of Luc mRNA used for designing the RNA oligomer is shown in FIG. 16 and SEQ ID NO: 33.
- luc oligo (SEQ ID NO: 25): UCGAAGAUCUCAGCGUA Chol-oligo luc (SEQ ID NO: 26): AA UCGAAGAUCUCAGCGUA oligo Scr (SEQ ID NO: 27): UCUUUGAGCACCUCCCAG Chol-oligo Scr (SEQ ID NO: 27): UCUUUGAGCACCUCCCAG siLuc (sense strand) (SEQ ID NO: 28): CUUACGCUGAGUACUUCGAdTdT siLuc (antisense strand) (SEQ ID NO: 29): UCGAAGUACUCAGCGUAGAGdTdT siScramble (siScr) (sense strand) (SEQ ID NO: 30): UUCCUCCGAACGUGUACACGUdTdT siScr (antisense strand) (SEQ ID NO: 31): ACGUGACACGUUCGGGAGAAdTdT
- siRNA was synthesized by request from Hokkaido System Science Co., Ltd. and used as it was.
- Hela-luc cells (Caliper LifeScience) (5,000 cells / well) constitutively expressing Luc were seeded on 96-well plates and incubated in DMEM (100 ⁇ L) containing 10 v / v% FBS for 24 hours. Thereafter, the medium was replaced with serum-free medium (Opti-MEM (trade name) (Thermo Fisher Scientific)) (100 ⁇ L), and a complex composed of Lipofectamine RNAiMax (Thermo Fisher Scientific) and RNA oligo or siRNA was added to the cells. After 4 hours of incubation, each added complex was removed. 24 hours after transfection, the cells were lysed using a Cell lysate buffer, and the expression level of luciferase in the 10 ⁇ L cell lysate was evaluated using a luminometer.
- siLuc, Luc Oligo, and Chol Oligo Luc indicate siRNA, unmodified RNA Oligo, and Chol-modified RNA Oligo targeting the Luc sequence, respectively.
- SiRNA, unmodified RNA Oligo and Chol-modified RNA Oligo are shown.
- oligo at a concentration of 8 nM was used, but endogenous gene expression did not decrease at that concentration. Since the decrease in endogenous gene expression was not observed unless the concentration was as high as 1,000 times that of siRNA, the effect on the endogenous gene is assumed to be very slight. As shown in FIG.
- RNA oligomer group having the same sequence as the antisense strand of siRNA and the other sequence RNA oligomer group did not knock down the endogenous gene as compared with siRNA. From the above results, it was confirmed that the RNA oligomer functionalizes mRNA without inhibiting the endogenous gene.
- Example 1-13 Investigation by PEG-Plys PEG-PLys was synthesized according to a report (K. Osada et al., Biomaterials 33, 325-332, (2012)) (Scheme 3). The synthesis scheme is as follows.
- MeO-PEG-NH 2 400 mg was taken, dissolved in benzene and lyophilized overnight. After lyophilization, MeO-PEG-NH 2 and NCA-Lys (TFA) were completely dissolved in 0.5M dimethylformamide (DMF) solvent under Ar atmosphere. NCA-Lys (TFA) solution was added to the MeO-PEG-NH 2 solution and stirred at 25 ° C. for 3 days. The reaction solution was reprecipitated in a mixed solution of n-hexane / ethyl acetate (3: 2), and PEG-PLys (TFA) was recovered. Thereafter, PEG-PLys (TFA) was vacuum-dried to obtain a white powder.
- DMF dimethylformamide
- Example 1-2 Gluc mRNA prepared in Example 1-2 or Gluc mRNA hybridized with the following RNA oligomer prepared in Example 1-3 was used.
- Chol-overhang 2base (1) Chol-overhang 2base (2) Chol-overhang 2base (3) Chol-overhang 2base (4) Chol-overhang 2base (5)
- PEG-PLys and mRNA were independently dissolved in 10 mM HEPES buffer (pH 7.4).
- the concentration of PEG-PLys was adjusted so that ((PLys positive charge number) / (mRNA negative charge number)) (N + / P ⁇ ratio) was 2 at pH 7.4.
- the PEG-PLys solution was added to the mRNA solution so that the final mRNA concentration was 33.3 ⁇ g / mL to prepare PMs.
- Example 1-14 Blood stability test using mice Here, Gluc mRNA prepared in Example 1-2 or Gluc mRNA hybridized with the following RNA oligomer prepared in Example 1-3 was used.
- Chol-overhang 2base (1) Chol-overhang 2base (2) Chol-overhang 2base (3) Chol-overhang 2base (4) Chol-overhang 2base (5) Chol-overhang 2base (6) Chol-overhang 2base (7) Chol-overhang 2base (8) Chol-overhang 2base (9) Chol-overhang 2base (10)
- PEG-PAsp (DET) -Chol and mRNA were independently dissolved in 10 mM HEPES buffer (pH 7.4).
- the concentration of PEG-PAsp (DET) -Chol is 1.5 ((number of positive charges of PAsp (DET)) / (number of negative charges of mRNA)) (N + / P ⁇ ratio) at pH 7.4. Adjusted as follows. PMs were prepared by adding a PEG-PAsp (DET) -Chol solution to the mRNA solution so that the final mRNA concentration was 200 ⁇ g / mL.
- Example 1-15 Local administration of PMs to lungs using mice
- Gluc mRNA prepared in Example 1-2 or Gluc mRNA hybridized with the following RNA oligomer prepared in Example 1-3 is used. It was.
- Chol-overhang 2base (1) Chol-overhang 2base (2) Chol-overhang 2base (3) Chol-overhang 2base (4) Chol-overhang 2base (5)
- the trachea of a Balb / C mouse (female, 6 weeks old) was incised, and 50 ⁇ L of a PMs solution containing 1.67 ⁇ g of mRNA was directly administered to the lungs using a nebulizer. After 24 hours, the mouse lungs were removed and homogenized, and the amount of Gluc protein contained therein was quantified with a luminometer. In addition, for the purpose of quantifying the amount of Gluc mRNA remaining in the lung using the lung 4 hours after administration, mRNA was extracted using RNeasy Mini Kit (QIAGEN), and the extracted RNA was reverse transcribed into cDNA. Thereafter, the remaining cDNA was quantitatively evaluated by qRT-PCR. At this time, the mRNA expression level was normalized based on the amount of actin contained in the tissue.
- FIG. 13 (A) significantly higher protein expression efficiency was obtained with mRNA hybridized with five Chol-modified oligomers than with unhybridized mRNA.
- FIG. 13B the amount of mRNA remaining in the lung tissue without being degraded is significantly increased by hybridizing five Chol-modified oligomers, so that stability in vivo It became clear that improved.
- the expression levels of (c) interferon ⁇ and (d) interleukin 6 in the lung tissue after administration are significantly changed by hybridization of 5 non-hybridized mRNA and 5 chol-modified oligomers. However, it was considered to have been secured because it remained low.
- FIG. 13B As described above, as a result of improvement in stability (FIG. 13B), it was found that expression was improved (FIG. 13A). This shows that it is also effective in vivo.
- Example 1-15 Preparation of polyethylene glycol (PEG) -modified mRNA PEGylated mRNA was prepared as follows.
- RNA secondary structure prediction software http://rtips.dna.bio.keio.ac.jp/ipknot/) predicts the secondary structure of Gluc mRNA, and the RNA strand has no secondary structure RNA oligomers were designed.
- the RNA oligomer was synthesized by Gene Design, including PEG modification at the 5 ′ end. Here, linear PEG having a weight average molecular weight of 12,000 was used. And the following 5 'terminal PEG modification RNA oligomer was purchased from Gene Design.
- Sequence p1 (SEQ ID NO: 34): 5′-PEG-ACUCUUUGUCGCCUUCG-3 ′
- Sequence p2 (SEQ ID NO: 35): 5′-PEG-CUCGGCCACAGCGAUGC-3 ′
- Sequence p3 (SEQ ID NO: 36): 5′-PEG-UCUUUGAGCACCUCCCAG-3 ′
- Sequence p4 (SEQ ID NO: 37): 5′-PEG-CUCUAGUAUGCAUGCUCG-3 ′
- Sequence p5 (SEQ ID NO: 38): 5′-PEG-GCGGGCAGCCACUCUCUG-3 ′
- Sequence p6 (SEQ ID NO: 39): 5′-PEG-AUCUCAGGAAUGUCGAC-3 ′
- Sequence p7 (SEQ ID NO: 40): 5′-PEG-GCAGCCAGCUUUCCGGG-3 ′
- Sequence p8 (SEQ ID NO: 41):
- Example 1-16 to 18 the mRNA prepared in Example 1-3 was used as mRNA.
- Hybridization was performed by adding 1 equivalent of RNA oligomer to mRNA, heating at 65 ° C. for 5 minutes, and cooling to 30 ° C. over 10 minutes. This produced PEGylated mRNA.
- Example 1-16 Change in translation efficiency due to hybridization of PEG-modified RNA oligomer to mRNA mRNA in which PEG-modified RNA oligomer was hybridized at 1, 5, 10, or 15 sites was used. In each experiment of 1, 5, 10, and 15 PEGRNA-modified oligomers, the following PEG-modified RNA oligomer prepared in Example 1-15 was used.
- the protein translation efficiency in the cell-free system of the prepared mRNA sample was evaluated using Rabbit Reticulocyte Lysate System, Nuclease treated (Promega Co., Madison, WI).
- a sample solution containing 300 ng of GLuc mRNA was added to Rabbit reticulocyte lysate and incubated at 30 ° C. for 90 minutes, and then the luminescence intensity of 10 ⁇ L of the reaction solution was quantified using Renilla Luciferase assay kit (Promega).
- Mitras LB 940 (Berthold technologies Co.) was used.
- Example 1-17 Stabilization effect by hybridization of PEG-modified RNA oligomer to mRNA mRNA in which PEG-modified RNA oligomer was hybridized at 1, 5, 10, or 15 sites was used.
- PEG-modified RNA oligomer Stabilization effect by hybridization of PEG-modified RNA oligomer to mRNA mRNA in which PEG-modified RNA oligomer was hybridized at 1, 5, 10, or 15 sites was used.
- the following PEG-modified oligomers prepared in Example 1-15 were used.
- the test procedure for confirming stability against FBS is as shown in FIG.
- a sample containing 100 ng of GLuc mRNA was incubated at 37 ° C. for 15 minutes in a 0.5% Fetal Bovine Serum (FBS, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan) solution. Thereafter, 350 ⁇ L of RLT buffer (Quiag, Hilden, Germany) containing 1 v / v% 2-mercaptoethanol was added, incubated at 65 ° C. for 5 minutes, and then rapidly cooled on ice to denaturate the PEG-RNA oligomer.
- FBS Fetal Bovine Serum
- Reverse-transcribed cDNA was quantitatively evaluated by quantitative RT-PCR (qRT-PCR).
- primers having the following sequences were used for qRT-PCR measurement.
- Example 1-18 Expression Test of PEGylated mRNA 15 mRNAs hybridized with PEG-modified RNA oligomers were used. In the experiment with 15 PEG-modified oligomers, the following PEG-modified oligomers prepared in Example 1-15 were used.
- the mRNA expression test on cultured cells was performed as follows. Human hepatoma cells (HuH-7 cells) were seeded on a 96-well plate at 5,000 cells / well and incubated at a humidified with 5% CO 2 at 37 ° C for 24 hours. After removing the serum medium, 100 ⁇ L of serum-free medium (Opti-MEM, Thermo Fisher Scientific Inc., Waltham, Mass.) was added, and a sample solution containing 250 ng of Gluc mRNA was added. After 4 hours, the luminescence intensity in 10 ⁇ L of the supernatant was quantified using Renilla Luciferase assay kit (Promega). For the measurement, Mitras LB 940 (Berthold technologies Co.) was used.
- Example 2-1 Production of various double-stranded RNAs T7-Gluc plasmid was obtained from pCMV-Gluc control plasmid (New England BioLabs, Ipswich, MA, USA) with a Gluc coding sequence (SEQ ID NO: 57 and FIG. 33). It was prepared by inserting into the HindIII, Xba1 site of the vector (Promega).
- T7-Gluc poly A120 plasmid was prepared by inserting A120- (BsmB1 cleavage site) into the EcoR1-Bgl2 site of T7-Gluc plasmid.
- the Gluc sense strand was prepared by cleaving T7-Gluc poly A120 plasmid with BsmBI and transcribed with mMESSAGE mMACHINE T7 Ultra Kit (Thermo Fisher Scientific). When RNA is prepared with this kit, the 5 'end is Cap-modified.
- the Gluc antisense chain (including poly U) was cut with T7-Gluc poly A120 plasmid with HindIII, and transferred from MEGAscript (registered trademark) SP6 Transcribing Kit (ThermoFisciS6 promoter). It was produced by doing.
- MEGAscript registered trademark
- SP6 Transcribing Kit ThermoFisciS6 promoter
- the Gluc antisense chain (without poly U) is cut with T7-Gluc plasmid with HindIII, and transferred from MEGAscript (registered trademark) SP6 Transcribation Kit (Thermo Fisher Scientific 6 promoter). It was made with.
- poly U cuts T7-Gluc poly A120 plasmid with SmaI, and was transcribed from Sp6 promoter with MEGAscript (registered trademark) SP6 Transcribation Kit (Thermo Fisher Scientific).
- poly U is complementary to the entire sequence of poly A (120 bases) and downstream of it, a part of the 3 ′ UTR of mRNA (ie, a sequence having a base length of about 37% of 3 ′ UTR). Sequence (19 bases).
- poly U further contains the sequence in the SP6 promoter and the restriction enzyme sequence used for cloning as other sequences (17 bases) upstream. That is, poly U used here has a sequence of 156 bases in length. It also has a triphosphate structure at the 5 'end.
- Gluc sense chain SEQ ID NO: 51 and FIG. 27
- Gluc antisense chain including poly U
- SEQ ID NO: 52 and FIG. 28 Gluc antisense chain (no poly U)
- poly U SEQ ID NO: 54 and FIG. 30
- the underlined portion is an open reading frame (ORF)
- the upstream of the ORF is 5'UTR (54 base length)
- the downstream of the ORF is 3'UTR (52 base length)
- 119A downstream thereof is a poly A sequence.
- the number of Poly A is theoretically incorporated into the template DNA at 120 bp, mRNA transcribed from the T7 promoter has 119 base A, and RNA transcribed from the Sp6 promoter has 120 base U.
- the number can be increased or decreased at the stage of DNA amplification or mRNA preparation.
- double-stranded RNA was prepared as follows. First, a solution in which an equimolar amount of a sense strand, an antisense strand or poly U was contained in a 10 mM Hepes buffer and an RNA concentration was 300 ⁇ g / ml was prepared. The solution was maintained at 65 ° C. for 5 minutes, and then hybridized by lowering to 30 ° C. over 10 minutes.
- FIG. 22 shows a schematic diagram of the prepared double-stranded RNA.
- 22 (A) shows mRNA: RNA
- FIG. 22 (B) shows mRNA: RNA poly U ( ⁇ )
- FIG. 22 (C) shows mRNA: poly U
- FIG. 22 (D) shows mRNA: poly U pppp (-).
- FIG. 22 there is a 5 ′ UTR upstream of the protein coding sequence of mRNA, and a 3 ′ UTR downstream.
- Example 2-2 Optimization of a double-stranded RNA vaccine using a dendritic cell line DC2.4 cells were seeded at 1,000,000 / well in a 6-well plate, the medium was changed after 24 hours, and the serum-free medium Opti- After substituting MEM (trade name) (Thermo Fisher Scientific), mRNA was administered at 2.5 ⁇ g / well using Lipofectamine (trade name) LTX (Thermo Fisher Scientific). After 4 hours, RNA was purified from the cells using RNeasy mini kit (QIAGEN), converted to complementary DNA (cDNA) using ReverseTra Ace qPCR RT Master Mix (TOYOBO), and then taqman gene expression assay (A) Then, the expression level of interferon ⁇ was examined. At this time, the expression level of actin b was normalized. The amount of Gluc protein contained in the medium was quantified with Renilla Luciferase Assay System (Promega).
- FIG. MRNA hybridized to the full length Although RNA could induce a strong inflammatory reaction (FIG. 23 (A)), the expression level of Gluc protein from mRNA was reduced by about 100 times compared to single-stranded mRNA (FIG. 23 ( B)). On the other hand, in mRNA: RNA poly U ( ⁇ ), the inflammatory reaction was significantly reduced compared to mRNA: RNA (FIG. 23 (A)), and the expression level of Gluc was similar to that of mRNA: RNA. (FIG. 23B). On the other hand, in the case where only the poly U portion was hybridized, in addition to the strong inflammatory reaction as seen in mRNA: RNA (FIG.
- the protein expression level from mRNA was also one.
- the level was almost the same as that of the strand mRNA (FIG. 23B).
- the 5 ′ end of the antisense strand RNA is triphosphorylated, and this is recognized by the intracellular nucleic acid receptor RIG-I and is known to induce a strong inflammatory reaction. . Therefore, in order to examine the relationship between triphosphate and inflammatory reaction, when mRNA hybridized with poly U excluding triphosphate was introduced, the inflammatory reaction was slightly reduced as compared with triphosphorylated poly U. Therefore, it was revealed that a stronger inflammatory reaction is elicited when the RNA oligomer has a 5'-terminal triphosphate.
- RNA poly U did not cause much inflammation, which strongly suggests that triphosphate recognition by RIG-I differs depending on the complementary strand used.
- poly U the 5 'end is exposed at the end of the mRNA, and triphosphate may be sterically easily recognized by RIG-I.
- the sequence around triphosphate contains a lot of U, but AU binding is weak. It is assumed that the mobility of triphosphoric acid has increased and it has become easier to recognize. Thus, it was strongly suggested that the selection of the complementary strand may be important for the innate immune response via RIG-I.
- Example 2-3 Administration of poly U hybridized mRNA into lymph node mRNA: poly U was prepared in the same manner as in Example 2-2. 10 ⁇ L of 10 mM Hepes solution containing 3 ⁇ g of Gluc mRNA was administered to the inguinal lymph nodes of C57BL6N mice. After 4 hours, the inguinal lymph nodes were collected, lysed with Passive lysis buffer (Promega), and the Luc expression level was quantified with Renilla Luciferase Assay System (Promega).
- poly U-hybridized mRNA elicits a strong inflammatory reaction even in vivo without significantly impairing translation efficiency.
- Example 2-4 Induction of Cellular Immunity by Poly U Hybridized mRNA T7-OVA poly A120 plasmid was obtained by using an OVA coding sequence (SEQ ID NO: 58 and FIG. 34), which had been codon-optimized by Genscript, pSP73 vector ( Promega) was inserted into the XhoI and EcoR1 sites.
- the OVA sense chain was prepared by cleaving T7-OVA poly A120 plasmid with BsmBI and transferring it from the T7 promoter with mMESSAGE mMACHINE T7 Ultra Kit (Thermo Fisher Scientific).
- poly U was prepared by cleaving T7-Gluc poly A120 plasmid with EcoRI and transcribed from Sp6 promoter with MEGAscript (registered trademark) SP6 transcription kit (Thermo Fisher Scientific).
- poly U is a sequence complementary to the entire sequence of poly A (120 bases), and downstream thereof, a part of 3′UTR of mRNA (that is, a sequence having a base length of about 83% of 3′UTR).
- the poly U used here further includes the sequence in the SP6 promoter and the restriction enzyme sequence used for cloning as other sequences (17 bases). That is, poly U used here has a sequence of 142 bases in length. It also has a triphosphate structure at the 5 ′ end.
- the underlined portion is an open reading frame (ORF)
- the upstream of the ORF is 5′UTR (16 bases)
- the downstream of the ORF is 3′UTR (6 bases).
- 119A downstream is the poly A sequence.
- the number of A and U is the same as in Example 2-1.
- the mRNA transcribed from the T7 promoter has 119 bases A
- the RNA transcribed from the Sp6 promoter has 120 bases U. However, the number can be increased or decreased at the stage of DNA amplification or mRNA preparation.
- OVA-expressed mRNA (mRNA: poly U) hybridized with poly U was prepared in the same manner as in Example 2-2. Specifically, a solution containing an equimolar amount of sense strand, antisense strand, or poly U in 10 mM Hepes buffer and an RNA concentration of 300 ⁇ g / ml was prepared. The solution was maintained at 65 ° C. for 5 minutes, and then hybridized by lowering to 30 ° C. over 10 minutes.
- FIG. 25 (A) shows the procedure of the following experiment.
- 10 ⁇ L of 10 mM Hepes solution containing 3 ⁇ g of OVA mRNA was administered to the inguinal lymph nodes of C57BL6N mice. Seven days later, spleen cells were collected, and an Enzyme-Linked ImmunoSpot (ELISPOT) assay was performed using an IFN- ⁇ ELISpot PLUS and a Mouse ( ⁇ ) HRP kit (MABTECH).
- ELISPOT Enzyme-Linked ImmunoSpot
- 250,000 cells / well were plated on a 96-well plate. After culturing for 24 hours at a final OVA concentration of 10 ⁇ g / mL, the number of IFN- ⁇ producing cells was counted.
- FIG. 25 (B) The result is shown in FIG.
- the vertical axis in FIG. 25 (B) indicates the number of splenocytes that produced IFN- ⁇ in response to OVA, and serves as an index of cellular immunity.
- cellular immunity was hardly induced with single-stranded OVA mRNA, whereas OVA mRNA (mRNA: poly U) hybridized with poly U was hybridized. A significant cellular immune response was observed.
- Example 2-5 Induction of humoral immunity by poly U hybridized mRNA OVA mRNA was administered to C57BL6N mice in the same manner as in Example 2-4, and blood was collected 7 days later (FIG. 26 (A)). . Anti-OVA IgG in the serum was quantified with Mouse Anti-OVA IgG Antibody Assay Kit (Condolex).
- Example 2-6 Optimization of double-stranded RNA vaccine using dendritic cells
- protein expression from mRNA in dendritic cells (DC 2.4 cells) The amount (ie luciferase expression level) was quantified.
- D.C. C. Experiments were performed by placing 2.4 cells in a 96-well plate at 40,000 / well.
- the following three were used as RNA oligomers.
- poly U chain length of a sequence complementary to 3′UTR: 5 bases
- SEQ ID NO: 56, FIG. 36 (B) poly U (chain length of the sequence complementary to 3′UTR: 19 bases)
- SEQ ID NO: 54, FIG. 36 (B) poly U (chain length of complementary sequence to 3′UTR: 50 bases) (SEQ ID NO: 59, FIG. 36 (B))
- Poly U (chain length of a complementary sequence to 3′UTR: 5 bases) (SEQ ID NO: 56) is a part of the 3′UTR of mRNA (ie, 3′UTR (52 bases long)). A sequence (5 bases) complementary to a 10% base length sequence). Further, poly U (chain length of a sequence complementary to 3′UTR: 19 bases) is a sequence having a base length of about 36% of a part of 3′UTR of mRNA (that is, 3′UTR (52 bases long)). ) To the complementary sequence (19 bases).
- Poly U (chain length of complementary sequence to 3′UTR: 50 bases)” was obtained by cleaving T7-Gluc poly A120 plasmid with NotI, and using MEGAscript (registered trademark) SP6 Transcriter Kit (Thermo Fisher Science 6). It was prepared by transcription from a promoter (FIG. 36 (A)).
- poly U is a sequence complementary to the entire sequence of poly A (120 bases), and downstream thereof, a portion of 3′UTR of mRNA (ie, about 96% of 3′UTR (52 bases long)) Sequence (50 bases) complementary to the base length sequence of
- the poly U used here further includes the sequence in the SP6 promoter and the restriction enzyme sequence used for cloning as other sequences (17 bases). That is, poly U used here has a sequence of 187 bases in length. In addition, it has a triphosphate structure at the 5 ′ end.
- RNA oligomer hybridization A synthetic RNA oligomer was prepared as follows. First, for the first sequence complementary to Gluc mRNA, the secondary structure of Gluc mRNA is determined using RNA secondary structure prediction software (http://rtips.dna.bio.keio.ac.jp/ipknot/). As predicted, an RNA oligomer was designed for the portion where the RNA strand had no secondary structure. The overhang sequence was designed using A or U so as not to hybridize with the mRNA strand as much as possible. Regarding the second sequence complementary to the 5′ppp-RNA oligomer, first, the sequence of the 5′ppp-RNA oligomer was designed, and a second sequence complementary to the sequence was obtained.
- a GU repeat sequence was used in the 5'ppp-RNA oligomer. This is because in vitro transcription in a system that does not contain ATP suppresses the generation of by-products of complementary strands. It is characteristic that secondary structure is not formed by RNA itself.
- the second sequence was obtained as a sequence complementary to the 5′ppp-RNA oligomer, and the sequence was designed so that the triphosphorylated 5 ′ end of the 5′ppp-RNA oligomer was smooth. . .
- the synthetic RNA oligomer designed as such was requested, and from the 5 ′ side, a 17-base sequence complementary to Gluc mRNA, a 2-base overhang sequence, and a 24-base sequence complementary to the 5′ppp-RNA oligomer
- the following synthetic RNA oligomers were purchased: Synthetic RNA oligomers were purchased from Hokkaido System Science.
- Synthetic RNA oligomer sequence 1 (SEQ ID NO: 60): CAGCCACGCUUUCCCGGGCUACACACACACACACACACACACAACC
- Synthetic RNA oligomer sequence 2 (SEQ ID NO: 61): ACUCUUUGUCGCCUUCGAUCACACACACACACACACACACACC
- Synthetic RNA oligomer sequence 3 (SEQ ID NO: 62): GCGGCAGCCCAUUCUGUACACACACACACACACACACACACACACACACACACACACACACACACACC
- a 5'ppp-RNA oligomer was prepared as follows. First, DR274 vector (addgene) was cleaved with BsaI, and the hybridized two kinds of oligomers were inserted therein.
- DNA oligomer (SEQ ID NO: 63): TAGGTTGTGTGTGTGTGTGTGTGTGTGTGTGGTGGGCCC
- DNA oligomer (SEQ ID NO: 64): AAACGGGCCCACACACACACACACACACACACACACACACACACACACACA
- a vector having the base sequence (SEQ ID NO: 65) shown in FIG. 41 was prepared.
- a 5'ppp-RNA oligomer was prepared by in vitro transcription by cleaving a vector having the base sequence (SEQ ID NO: 65) shown in FIG. 41 with ApaI and SnaBI.
- transcription of complementary strand RNA of the target sequence was suppressed by using a reaction solution that did not contain ATP.
- the following 5'ppp-RNA oligomer in which 5 'was triphosphorylated was prepared.
- 24nt 1 piece 5'ppp-RNA oligomer, synthetic RNA oligomer sequence 1 and Gluc mRNA mixed at a molar ratio of 1: 1: 1 and hybridized.
- 24nt 2 pieces 5'ppp-RNA oligomer, synthetic RNA oligomer sequence 1 and 2, and Gluc mRNA mixed at a molar ratio of 1: 1: 1: 1 and hybridized.
- Example 3-2 and 3-3 Gluc mRNA prepared in Example 1-3 was used. Hybridization was performed by heating at 65 ° C. for 5 minutes and cooling to 30 ° C. over 10 minutes.
- Example 3-3 “mRNA: polyU” prepared in Example 2-1 was used as “mRNA: pU”.
- Example 3-2 Immunostimulation DC2.4 cells were seeded at 400,000 / well in a 12-well plate, the medium was replaced after 24 hours, and replaced with serum-free medium Opti-MEM (trade name) (Thermo Fisher Scientific). Thereafter, 2.5 ⁇ g / well of mRNA was administered using Lipofectamine (trade name) LTX (Thermo Fisher Scientific). Four hours later, RNA was purified from cells using RNeasy mini kit (QIAGEN), converted to complementary DNA (cDNA) using ReverseTra Ace qPCR RT Master Mix (TOYOBO), and then taqman gene expression assay (Aqman gene expression assay) The expression levels of interferon ⁇ and interleukin 6 were examined. At this time, the expression level of actin b was normalized.
- Example 3-3 Protein translation After DC2.4 cells were seeded at 40,000 / well in 96 well plate, the medium was changed after 24 hours, and replaced with serum-free medium Opti-MEM (trade name) (Thermo Fisher Scientific). , MRNA was administered at 0.25 ⁇ g / well using Lipofectamine (trade name) LTX (Thermo Fisher Scientific). After 4 hours, the amount of Gluc protein was quantified with Renilla Luciferase Assay System (Promega).
- MRNA delivery is expected to be applied to medicine as a technique for safely and continuously supplying therapeutic proteins.
- it has been a major problem that mRNA is rapidly subjected to enzymatic degradation in vivo.
- the enzymatic degradation of mRNA when encapsulated in the polymer micelle is remarkably suppressed, and the mRNA introduction efficiency is successfully increased. did.
- the mRNA-encapsulating polymer micelle used here has shown excellent effects in therapeutic experiments on model animals with various diseases such as central nervous system diseases, motor sensory organ diseases, liver diseases, malignant tumors, etc. Research with a view to the future is underway.
- the composition of the polymer micelle varies depending on the target organ and administration method, but the technique of the first aspect of the present invention can be widely applied because it can stabilize micelles of various compositions.
- MRNA vaccine is positioned as a pharmaceutical with a completely different mechanism from conventional vaccines.
- Features include the ability to freely construct antigen proteins to be expressed and the induction of cellular immunity.
- DNA vaccine as a nucleic acid vaccine of the same type, but DNA has a risk of mutagenesis due to random insertion into the host genome, which is an obstacle to practical use, whereas mRNA has no risk.
- the development of vaccines using conventional single-stranded mRNA has been progressing mainly in the United States and Germany, but it has been inevitable to use an adjuvant in order to effectively induce an inflammatory reaction.
- the mRNA vaccine according to the second and third aspects of the present invention does not necessarily require an adjuvant, and can effectively induce an inflammatory response only with mRNA, and simultaneously and sympatricly with antigen presentation. Can elicit an inflammatory response.
- MRNA vaccine can be flexibly adapted according to the purpose and purpose, regardless of administration route (subcutaneous administration, intramuscular administration, transmucosal administration, etc.), transport carrier, etc.
- mRNA used in the mRNA vaccine is purified on the basis of a chemical reaction, and can be applied to any protein simply by changing the base sequence. These are clearly different merits from conventional vaccines.
- the vaccine according to the second and third aspects of the present invention is expected to have a wide market as a new vaccine system, such as individualized treatment for cancer and the like, and an infectious disease vaccine capable of quickly responding to virus mutation.
- Synthetic RNA SEQ ID NOs: 1-27 Synthetic RNA SEQ ID NOs: 28 to 31: Synthetic DNA / RNA SEQ ID NO: 32: synthetic DNA SEQ ID NO: 33: synthetic RNA SEQ ID NOs: 34 to 48: Synthetic RNA SEQ ID NOs: 49 and 50: synthetic DNA
- SEQ ID NOs: 51-56 Synthetic RNA
- SEQ ID NOs: 57 and 58 synthetic DNA
- SEQ ID NO: 59 Synthetic RNA
- SEQ ID NOs: 60-62 Synthetic RNA
- SEQ ID NOs: 63-65 Synthetic DNA
- SEQ ID NOs: 66-68 Synthetic RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
mRNAと、mRNAにハイブリダイズした少なくとも1つの修飾されたRNAオリゴマーとを含む二本鎖RNAを含む、機能化mRNA。
[1-1] 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを内包した前記mRNAの輸送担体であって、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されている、輸送担体。
[1-1A] 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを内包した前記mRNAの輸送担体であって、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、輸送担体。
[1-2] 前記RNA配列が15~23塩基の配列からなる、上記[1-1]又は[1-1A]に記載の輸送担体。
[1-3] 前記RNA配列が17塩基の配列からなる、上記[1-2]に記載の輸送担体。
[1-4] 前記化学修飾は、1~5塩基のオーバーハング配列を介してRNAオリゴマーの配列の5’末端又は3’末端になされたものである、上記[1-1]~[1-3]のいずれか1項に記載の輸送担体。
[1-5] 前記オーバーハング配列が2塩基の配列である、上記[1-4]に記載の輸送担体。
[1-6] 前記化学修飾が疎水性基による修飾である、上記[1-1]~[1-5]のいずれか1項に記載の輸送担体。
[1-7] 前記疎水性基による修飾がコレステロール修飾である、上記[1-6]に記載の輸送担体。
[1-8] 前記化学修飾がポリエレングリコール修飾である、上記[1-1]~[1-5]のいずれか1項に記載の輸送担体。
[1-9] 前記輸送担体が、高分子ミセル又は脂質性mRNAキャリアである、上記[1-1]~[1-8]のいずれか1項に記載の輸送担体。
[1-10] 上記[1-1]~[1-9]のいずれか1項に記載の輸送担体を含有する、医薬組成物。
[1-11] 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを輸送担体に内包させることを含み、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されている、輸送担体の安定化方法。
[1-11A] 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを輸送担体に内包させることを含み、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、輸送担体の安定化方法。
[1-12] 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを含む二本鎖RNAであって、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、二本鎖RNA。
[1-13] 前記RNA配列が15~23塩基の配列からなる、上記[1-12]に記載の二本鎖RNA。
[1-14] 前記RNA配列が17塩基の配列からなる、上記[1-13]に記載の二本鎖RNA。
[1-15] 前記化学修飾は、1~5塩基のオーバーハング配列を介してRNAオリゴマーの配列の5’末端又は3’末端になされたものである、上記[1-12]~[1-14]のいずれか1項に記載の二本鎖RNA。
[1-16] 前記オーバーハング配列が2塩基の配列である、上記[1-15]に記載の二本鎖RNA。
[1-17] 前記化学修飾が疎水性基による修飾である、上記[1-12]~[1-16]のいずれか1項に記載の二本鎖RNA。
[1-18] 前記疎水性基による修飾がコレステロール修飾である、上記[1-17]に記載の二本鎖RNA。
[1-19] 前記化学修飾がポリエレングリコール修飾である、上記[1-12~[1-16]のいずれか1項に記載の二本鎖RNA。
[1-20] 上記[1-12]~[1-19]のいずれか1項に記載の二本鎖RNAが輸送担体に内包されている、mRNA輸送担体。
[1-21] 前記輸送担体が、高分子ミセル又は脂質性mRNAキャリアである、上記[1-20]に記載の輸送担体。
[1-22] 上記[1-20]または[1-21]のいずれか1項に記載の輸送担体を含有する、医薬組成物。
[2-1] 抗原をコードするmRNAと、当該mRNAの少なくともpoly A配列にハイブリダイズした少なくとも1つのRNAオリゴマーからなる二本鎖RNAを含み、前記少なくとも1つのRNAオリゴマーは化学修飾されていない、mRNAワクチン。
[2-1A] 抗原をコードするmRNAと、当該mRNAの少なくともpoly A配列にハイブリダイズした少なくとも1つのRNAオリゴマーからなる二本鎖RNAを含み、前記少なくとも1つのRNAオリゴマーは化学修飾されていない又は化学修飾されている、mRNAワクチン。
[2-2] RNAオリゴマーは、10~500塩基配列からなる、上記[2-1]又は[2-1A]に記載のmRNAワクチン。
[2-3] RNAオリゴマーは、5’末端にトリリン酸構造を有する、上記[2-1]~[2-2]のいずれか1項に記載のmRNAワクチン。
[2-4] 二本鎖RNAは、mRNAの少なくともpoly A配列に1つのRNAオリゴマーがハイブリダイズしたものである、上記[2-1]~[2-3]のいずれか1項に記載のmRNAワクチン。
[2-5] 二本鎖RNAがネイキッドの形態である、上記[2-1]~[2-4]のいずれか1項に記載のmRNAワクチン。
[2-6] アジュバントと共に用いない、上記[2-1]~[2-5]のいずれか1項に記載のmRNAワクチン。
[2-7] 疾患の予防又は治療を必要とする対象において当該疾患の予防又は治療に用いるための、上記[2-1]~[2-6]のいずれか1項に記載のmRNAワクチン。
[2-8] 疾患の予防又は治療を必要とする対象に、上記[2-1]~[2-6]のいずれか1項に記載のmRNAワクチンを投与することを含む、疾患の予防又は治療方法。
[3-1] 抗原をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つの第1のRNAオリゴマーと、当該第1のRNAオリゴマーにハイブリダイズした第2のRNAオリゴマーからなる二本鎖RNAを含み、
第1のRNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(c)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列を、5’末端よりこの順に含むRNA配列、又は
(d)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、5’末端よりこの順に含むRNA配列
を含む、mRNAワクチン。
[3-2] 第1のRNAオリゴマーは、22~240塩基の配列からなる、上記[3-1]に記載のmRNAワクチン。
[3-3] 1つのmRNAにハイブリダイズさせる第1のRNAオリゴマーの数が、1~50個である、上記[3-1]または[3-2]に記載のmRNAワクチン。
[3-4] 第1のRNAオリゴマーは、前記(a)のRNA配列又は前記(b)のRNA配列を含み、第2のRNAオリゴマーは、5’末端にトリリン酸構造を有する、上記[3-1]~[3-3]のいずれか1項に記載のmRNAワクチン。
[3-5] 第1のRNAオリゴマーは、前記(c)のRNA配列又は前記(d)のRNA配列を含み、第1のRNAオリゴマーは、5’末端にトリリン酸構造を有する、上記[3-1]~[3-3]のいずれか1項に記載のmRNAワクチン。
[3-6] 第2のRNAオリゴマーが第1のRNAオリゴマーにハイブリダイズしている側の二本鎖RNAの末端が、平滑末端である、上記[3-1]~[3-5]のいずれか1項に記載のmRNAワクチン。
[3-7] 第2のRNAオリゴマーは10~200塩基の配列を含む、上記[3-1]~[3-6]のいずれか1項に記載のmRNAワクチン。
[3-8] 二本鎖RNAがネイキッドの形態である、上記[3-1]~[3-7]のいずれか1項に記載のmRNAワクチン。
[3-9] アジュバントと共に用いない、上記[3-1]~[3-8]のいずれか1項に記載のmRNAワクチン。
[3-10] 疾患の予防又は治療を必要とする対象において当該疾患の予防又は治療に用いるための、上記[3-1]~[3-9]のいずれか1項に記載のmRNAワクチン。
1.1.本発明の第1の態様の概要
mRNAの塩基修飾では、従来は、自由な化学修飾の設計が困難であった。そこで、本発明者らは、mRNAと相補的な配列を持つRNAオリゴマーに化学修飾を行い、それをmRNAにハイブリダイズさせることで、mRNAの化学修飾を行うことができないかと考えた(図1)。この場合、mRNA自体は天然のものであるため、翻訳の過程は障害されず、自由な化学修飾が可能になることが期待された。一方でハイブリダイズを行うことによる翻訳過程の障害も懸念されたため、まず、様々な鎖長のRNAオリゴマーをハイブリダイズさせ、翻訳効率への影響を調べた。すると、RNAオリゴマー鎖長を長くすればするほど翻訳効率が低下していく傾向にあることが明らかとなった。一方で、17~40塩基のRNAオリゴマーでは、ハイブリダイズに伴う発現の低下を十分に防ぐことができることがわかった(図2)。特に、17塩基のオリゴマーでは、ハイブリダイズに伴う発現の低下がほとんど見られなかった(図2)。これらのことから、12~40塩基のRNAオリゴマーを用いることで、翻訳効率を十分に維持することができることが分かった。
さらに本発明の第1の態様は、mRNA自体、又は様々な輸送担体(例えば、高分子ミセル)においてmRNAの酵素分解を抑制できる汎用性がある技術である。
本発明の第1の態様は、目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを含む二本鎖RNAであって、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、二本鎖RNAを提供する。
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、輸送担体を提供する。
いくつかの態様では、輸送担体に内包させるmRNAの量は、輸送担体中のカチオン電荷(+)とmRNAのアニオン電荷(-)の比(+/-比)において、例えば、0.5~200であり、好ましくは1~50であり、より好ましくは1~10である。
ここで用いるmRNAは、次のいずれかのものであってよい。
(1)5’Cap、5’UTR、コード領域、3’UTR、及びpoly Aをこの順に含むmRNA。
(2)5’Cap、5’UTR、コード領域、及びpoly Aをこの順に含むmRNA。
(3)5’UTR、コード領域、3’UTR、及びpoly Aをこの順に含むmRNA。
(4)5’UTR、コード領域、及びpoly Aをこの順に含むmRNA。
(5)5’Cap、5’UTR、コード領域、及び3’UTRをこの順に含むmRNA。
(6)5’Cap、5’UTR、コード領域をこの順に含むmRNA。
(7)5’UTR、コード領域、及び3’UTRをこの順に含むmRNA。
(8)5’UTR、コード領域をこの順に含むmRNA。
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含むRNA鎖である。
尚、「化学修飾」の定義には、5’末端のトリリン酸構造は含まれない。
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、mRNAの安定化方法を提供する。
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、輸送担体の安定化方法も提供する。
本発明の第1の態様は、前記二本鎖RNA又は輸送担体を含有する医薬組成物を提供する。医薬組成物は、mRNA、又はmRNAを内包する輸送担体を、対象の体内に送達することに用いられる。
本発明の第1の態様のmRNA送達用キットは、前記化学修飾されていないRNAオリゴマー又は化学修飾RNAオリゴマーをハイブリダイズしたmRNAを含むことを特徴とするものである。化学修飾されていないRNAオリゴマー又は化学修飾RNAオリゴマーをハイブリダイズしたmRNAは、輸送担体に内包されていてよい。あるいは、化学修飾されていないRNAオリゴマー又は化学修飾RNAオリゴマーをハイブリダイズしたmRNAは輸送担体に内包されていなくてもよく、すなわちネイキッドの形態でもよい。好ましくは、化学修飾されていないRNAオリゴマー又は化学修飾RNAオリゴマーをハイブリダイズしたmRNAは、輸送担体に内包されていている。前者の本発明の第1の態様のmRNA送達用キットは、輸送担体を含むことを特徴とするものである。当該キットは、例えば、前記化学修飾されていないRNAオリゴマー又は化学修飾RNAオリゴマーをハイブリダイズしたmRNA又は輸送担体を用いた各種疾患の治療方法に好ましく用いることができる。
2.1.本発明の第2の態様の概要
mRNA自体は免疫原性が低いために炎症反応を惹起しにくい。そのため、従来の一本鎖のmRNAを用いたワクチンは、効果的に炎症反応を惹起するためのアジュバント併用が避けられなかった。
本発明の第2の態様は、抗原をコードするmRNAと、当該mRNAの少なくともpoly A配列にハイブリダイズした少なくとも1つのRNAオリゴマーからなる二本鎖RNAを含み、前記少なくとも1つのRNAオリゴマーは化学修飾されていない又は化学修飾されている、mRNAワクチンを提供する。
mRNAは、メッセンジャーRNAを意味し、通常、5’非翻訳領域(5’UTR)とコード領域と3’非翻訳領域(3’UTR)とを含む。mRNAは、さらに、通常、5’末端のキャップ構造(5’Cap)と3’末端のpoly A配列を含む。
mRNAワクチンに用いるmRNAは、次のいずれかのものであってよい。
(1)5’Cap、5’UTR、コード領域、3’UTR、及びpoly Aをこの順に含むmRNA。
(2)5’Cap、5’UTR、コード領域、及びpoly Aをこの順に含むmRNA。
(3)5’UTR、コード領域、3’UTR、及びpoly Aをこの順に含むmRNA。
(4)5’UTR、コード領域、及びpoly Aをこの順に含むmRNA。
mRNAワクチンに用いるmRNAは、公知の方法により、目的遺伝子をコードするテンプレートDNAをin vitro環境下で転写することで作製することができる。例えば、Blood 108(13)(2006)4009-17に記載の方法に従って、作製することができる。具体的には、タンパク質コード配列の下流にpoly A/T鎖が組み込まれた鋳型DNAをpoly A/T鎖のすぐ下流で切断し、翻訳酵素、ヌクレオシド、5’キャップアナログを含むバッファー溶液中にてin vitro転写を行い、その後、mRNAを精製することで作製する。mRNAのより具体的な調製方法は、後述の実施例に記載の通りである。
mRNAの調製及び修飾は、公知の方法又はそれに準ずる方法により行うことができる。
本発明の第2の態様では、mRNAの少なくともpoly A配列に少なくとも1つのRNAオリゴマーがハイブリダイズしている。また、当該RNAオリゴマーは、化学修飾を含まないものである。
(1)mRNAのpoly A配列中の連続する配列。
(2)mRNAの3’UTRとpoly A配列中の連続する配列。
(3)mRNAのコード領域とpoly A配列中の連続する配列。
(a)上記(1)~(3)のいずれかの連続する配列に相補的な配列を有するRNAオリゴマー、または、
(b)上記(1)~(3)のいずれかの連続する配列に相補的な配列と90%以上の同一性を有するRNA配列を有し、かつ、mRNAにハイブリダイズするRNAオリゴマー。
「mRNAにハイブリダイズする」とは、後述のハイブリダイズ条件で、RNAオリゴマーがmRNAにハイブリダイズすることを意味する。
いくつかの態様のRNAオリゴマーは、化学修飾を含まないものである。別のいくつかの態様のRNAオリゴマーは、又は化学修飾を含むものである。化学修飾は、例えば、疎水性基による修飾が挙げられる。疎水性基による修飾としては、コレステロール修飾、及びトコフェロール修飾が挙げられる。また、化学修飾としては、例えば、ポリエチレングリコール修飾も挙げられる。
尚、「化学修飾」の定義には、5’末端のトリリン酸構造は含まれない。
二本鎖RNAは、前述のmRNAに少なくとも1つの前述のRNAオリゴマーがハイブリダイズしたものである。
別のいくつかの態様では、二本鎖RNAは、RNAオリゴマーの5’末端のトリリン酸構造を有さない。トリリン酸化を除く方法は、公知の方法又はそれに準ずる方法で行うことができる。トリリン酸化を除く方法としては、例えば、後述の実施例のように、Antarctic phosphatase(New England Biolabs,cat.no.M0289S)を用いる方法が挙げられる。
別のいくつかの態様では、二本鎖RNAは、輸送担体に内包される形態である。輸送担体は、二本鎖mRNAを内包して、対象の体内の好適な箇所に送達することができるものであればよく、特に限定されない。輸送担体は脂質性mRNAキャリア、又はカチオン性ポリマー複合体であり、より好ましくは、高分子ミセル又は脂質性mRNAキャリアである。
いくつかの好ましい態様では、RNAワクチンは、アジュバントと共には用いない。
別のいくつかの態様では、RNAワクチンは、アジュバントと共に用いる。アジュバントと共に用いる場合、RNAワクチンは、アジュバントと共に製剤化されてもよい。アジュバントは、免疫反応を増強するのに好適な任意の化合物である。そのようなアジュバントは公知であり、当業者であれば、任意のアジュバントの中から適切なものを選択することができる。
mRNAワクチンは、疾患の予防又は治療を必要とする対象において当該疾患の予防又は治療に用いることができる。
本発明の第2の態様のキットは、前記mRNAワクチンを含むことを特徴とするものである。当該キットは、例えば、前記RNAワクチンを用いた前記各種疾患の治療方法に好ましく用いることができる。
キットは、前記mRNAワクチン以外に、他の構成要素を含んでいてもよい。他の構成要素としては、例えば、各種バッファー及び使用説明書(使用マニュアル)を挙げることができる。キットには、アジュバントを含めてもよいし、含めなくてもよい。好ましくは、キットは、アジュバントを含めない。
3.1.本発明の第3の態様の概要
二本鎖RNA認識において細胞内受容体であるRIG-Iが重要な役割を担うことが知られている。そして、RIG-Iと二本鎖RNAの結合において、片方のRNA鎖の5’末端がトリリン酸化されていることが重要であるとの報告もある。5’末端がトリリン酸化された第2のRNAオリゴマーを第1のRNAオリゴマーにハイブリダイズし、これをmRNAにハイブリダイズした二本鎖mRNAを作製した。図37の二本鎖mRNAは、1つのmRNAにつき、5つのRNAオリゴマーをハイブリダイズさせたものを例示している。一方、後述の実施例では、1つのmRNAにつき、1~3個のRNAオリゴマーをハイブリダイズさせたものを用いた。これらの二本鎖mRNAを用いた場合、ハイブリダイズさせていないmRNAと比べ、免疫賦活化作用が向上し(図38及び39)、また、mRNAの発現効率は維持された(図40)。このとき、免疫賦活化作用は、mRNAにハイブリダイズする二本鎖RNAオリゴマーの個数が増えるにしたがって向上した(図38及び39)。従って、RIG-IがRNAオリゴマーをハイブリダイズさせたmRNAに対する炎症反応に強く関わっていることが示唆された。
また、本発明の第3の態様のmRNAワクチンは、第2の態様のmRNAワクチンと比べ、RIG-I認識に必要な平滑5’末端トリリン酸化構造を構築するのが容易である。
さらに、本発明の第3の態様のmRNAワクチンは、in vitro転写で第2のRNA鎖を調製する際に副産物として目的RNAの相補鎖RNAが転写されるが、第2の態様の特定のmRNAワクチンと比べ、その副産物の産生を容易に回避できる。
本発明の第3の態様は、抗原をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つの第1のRNAオリゴマーと、当該第1のRNAオリゴマーにハイブリダイズした第2のRNAオリゴマーからなる二本鎖RNAを含み、
第1のRNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(c)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列を、5’末端よりこの順に含むRNA配列、又は
(d)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、5’末端よりこの順に含むRNA配列
を含む、mRNAワクチンを提供する。
mRNAは、メッセンジャーRNAを意味し、通常、5’非翻訳領域(5’UTR)とコード領域と3’非翻訳領域(3’UTR)とを含む。mRNAは、さらに、通常、5’末端のキャップ構造(5’Cap)と3’末端のpoly A配列を含む。
mRNAワクチンに用いるmRNAは、次のいずれかのものであってよい。
(2)5’Cap、5’UTR、コード領域、及びpoly Aをこの順に含むmRNA。
(3)5’UTR、コード領域、3’UTR、及びpoly Aをこの順に含むmRNA。
(4)5’UTR、コード領域、及びpoly Aをこの順に含むmRNA。
本発明の第3の態様では、少なくとも1つの第1のRNAオリゴマーがmRNAにハイブリダイズする。また、さらに第2のRNAオリゴマーが第1のRNAオリゴマーにハイブリダイズしている。
(a)mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(c)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列を、5’末端よりこの順に含むRNA配列、又は
(d)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、5’末端よりこの順に含むRNA配列
を含むRNA鎖である。
(ii)第2のRNAオリゴマーが第1のRNAオリゴマーにハイブリダイズしている側の二本鎖RNAの末端が、5’末端トリリン酸化構造、好ましくは平滑5’末端トリリン酸化構造を取るようにすること、
(iii)第2のRNA配列及び第2のRNAオリゴマーがmRNA上の配列にハイブリダイズしないこと、及び
(iv)第1及び第2のRNAオリゴマーが2次構造を作らないこと。
すなわち、第1のRNAオリゴマーが前記(a)のRNA配列又は前記(b)のRNA配列であるときは、5’末端にトリリン酸化構造を有する第2のRNAオリゴマーをin vitro転写させることで第2のオリゴマーを調製する。好ましくは、このとき、第2のオリゴマーの5’末端と、第1オリゴマーの3’末端がハイブリダイズしたときに平滑末端になるように第1のオリゴマーを調製する。そして、このような第1及び第2のRNAオリゴマーが調製できるように、第1のRNAオリゴマーの第2のRNA配列を設計する。
一方、第1のRNAオリゴマーが前記(c)のRNA配列又は前記(d)のRNA配列であるときは、第1のRNAオリゴマーをin vitro転写させることで第1のRNAオリゴマーを調製する。好ましくは、このとき、第1のRNAオリゴマーの5’末端と、第2のRNAオリゴマーの3’末端がハイブリダイズしたときに平滑末端になるよう第2オリゴマーを調製する。そして、このような第1及び第2のRNAオリゴマーが調製できるように、第1のRNAオリゴマーの第2のRNA配列を設計する。
尚、「化学修飾」の定義には、5’末端のトリリン酸構造は含まれない。
ここで、「二本鎖RNA」は、前述のmRNAに少なくとも1つの前述の第1のRNAオリゴマーがハイブリダイズし、かつ第1のRNAオリゴマーに第2のRNAオリゴマーがハイブリダイズしたものである。また、第1のRNAオリゴマーと、第1のRNAオリゴマーにハイブリダイズした第2のRNAオリゴマーからなるものを、「二本鎖RNAオリゴマー」という場合がある。
そこで、ここでは、1つのmRNAにハイブリダイズさせる二本鎖RNAオリゴマーの個数を調節することを含む、免疫反応を調節する方法が提供される。
別のいくつかの態様では、二本鎖RNAは、輸送担体に内包される形態である。輸送担体は、二本鎖mRNAを内包して、対象の体内の好適な箇所に送達することができるものであればよく、特に限定されない。輸送担体は脂質性mRNAキャリア、又はカチオン性ポリマー複合体であり、より好ましくは、高分子ミセル又は脂質性mRNAキャリアである。
いくつかの好ましい態様では、RNAワクチンは、アジュバントと共には用いない。
別のいくつかの態様では、RNAワクチンは、アジュバントと共に用いる。アジュバントと共に用いる場合、RNAワクチンは、アジュバントと共に製剤化されてもよい。アジュバントは、免疫反応を増強するのに好適な任意の化合物である。そのようなアジュバントは公知であり、当業者であれば、任意のアジュバントの中から適切なものを選択することができる。
mRNAワクチンは、疾患の予防又は治療を必要とする対象において当該疾患の予防又は治療に用いることができる。
予防又は治療する疾患は、例えば、がん、ウイルス性感染症、細菌性感染症、真菌感染症、原生生物感染症、及び自己免疫疾患を挙げることができる。前述のmRNAのコード領域がコードする抗原を、予防又は治療する疾患に応じて適切に選択することで、当該疾患を予防又は治療することができる。
本発明の第3の態様のキットは、前記mRNAワクチンを含むことを特徴とするものである。当該キットは、例えば、前記RNAワクチンを用いた前記各種疾患の治療方法に好ましく用いることができる。
キットにおいて、前記mRNAワクチンの保存状態は、限定はされず、その安定性(保存性)及び使用容易性等を考慮して溶液状又は粉末状等の状態を選択できる。
キットは、前記mRNAワクチン以外に、他の構成要素を含んでいてもよい。他の構成要素としては、例えば、各種バッファー及び使用説明書(使用マニュアル)を挙げることができる。キットには、アジュバントを含めてもよいし、含めなくてもよい。好ましくは、キットは、アジュバントを含めない。
1.1.PEG-PAsp(DET)-Cholの合成
PEG-PAsp(DET)-Cholは既報に従い合成した(Oba,M.,et al.,Biomaterials(2011)32,p.652-663)(Scheme1)。合成スキームは以下のとおりである。
また、同様のPEG-PBLAのアミノリシス反応によりPEG-PAsp(DET)を合成した(Scheme2)。
mRNAは鋳型DNAよりin vitro転写により調製するが、ここで鋳型DNAは以下のように作製した。まず、T7-Gluc plasmidは、pCMV-Gluc control plasmid(New England BioLabs,Ipswich,MA,USA)からGlucコード配列(図15および配列番号32)をpSP73ベクター(Promega)のHindIII,Xba1サイトに挿入することで作製した。その後、T7-Gluc poly A120 plasmidを、T7-Gluc plasmidのEcoR1-Bgl2サイトにA120-(BsmBI切断部位)を挿入することで作製した。その後、BsmBIで切断したのち、T4 DNA Polymerase(タカラバイオ)で末端の平滑化を用い、以下のin vitro転写に用いた。
RNAオリゴマーを次のようにして設計し、調製した。RNA2次構造予測ソフトウェア(http://rtips.dna.bio.keio.ac.jp/ipknot/)にて、Gluc mRNAの2次構造を予測し、RNA鎖が2次構造を持たない部分に対してRNAオリゴマーを設計した。RNAオリゴマーは、5’末端又は3’末端のコレステロール修飾を含めて、北海道システムサイエンス社にて、依頼合成した。尚、下記RNAオリゴマーの配列中の下線部はオーバーハング配列を示す。また、ミスマッチChol-RNAオリゴは、mRNAとハイブリダイズしない19merのChol修飾ポリAである。「Chol-overhang」は、RNAオリゴマーの5’末端がコレステロール修飾されていることを示し、「Chol―overhang 3’」はRNAオリゴマーの3’末端がコレステロール修飾されていることを示す。
17mer(1)(配列番号2):UCUUUGAGCACCUCCAG
17mer(2)(配列番号3):CUCUAGAUGCAUGCUCG
17mer(3)(配列番号4):CUCGGCCACAGCGAUGC
17mer(4)(配列番号5):GCGGCAGCCACUUCUUG
17mer(5)(配列番号6):AUCUCAGGAAUGUCGAC
40mer(配列番号8):CUUUCCGGGCAUUGGCUUCCAUCUCUUUGAGCACCUCCAG
60mer(配列番号9):ACAGCCCCUGGUGCAGCCAGCUUUCCGGGCAUUGGCUUCCAUCUCUUUGAGCACCUCCAG
Chol-overhang 2base(1)(配列番号10):AAUCUUUGAGCACCUCCAG
Chol-overhang 5base(1)(配列番号11):AAUAAUCUUUGAGCACCUCCAG
Chol-overhang 2base(2)(配列番号12):AACUCUAGAUGCAUGCUCG
Chol-overhang 5base(2)(配列番号13):AAUAACUCUAGAUGCAUGCUCG
Chol―overhang 2base(4)(配列番号15):AAGCGGCAGCCACUUCUUG
Chol―overhang 2base(5)(配列番号16):AUAUCUCAGGAAUGUCGAC
Chol―overhang 2base(7)(配列番号18):AAACUCUUUGUCGCCUUCG
Chol―overhang 2base(8)(配列番号19):AAUUGAGGCAGCCAGUUGU
Chol―overhang 2base(9)(配列番号20):UAGUGGGACAGGCAGAUCA
Chol―overhang 2base(10)(配列番号21):AAUUGAAGUCUUCGUUGUU
培養細胞を用いた評価では、RAW264.7細胞を12wellプレートに300,000cells/wellとなるように播種し、10v/v%ウシ胎児血清(FBS)を含むDulbecco’s Modified Eagle Medium(DMEM)中で24hインキュベーションした。インキュベーション後、DMEMをOpti-MEM(商品名)(Thermo Fisher Scientific)に置き換え、実施例1-2で調製したGluc mRNA又は実施例1-3で調製したRNAオリゴマー(17mer(1),23mer,40mer又は60mer)をハイブリダイズしたGluc mRNAが1μg/wellとなるようにLipofectamine(商品名) LTX(Thermo Fisher Scientific)とmRNAからなるコンプレックスを添加した。トランスフェクションから4h後、培地を回収し、そこに含まれるGlucの量をルミノメータにて評価した。
ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製したRNAオリゴマー(overhang 2base(1)又はChol-overhang 2base(1))をハイブリダイズしたGluc mRNAを用いた。
その結果を、表1及び2、図3に示す。
ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製した以下のRNAオリゴマーをハイブリダイズしたGluc mRNAを用いた。
Chol-overhang 0(1)
Chol-overhang 2base(1)
Chol-overhang 5base(1)
ミスマッチChol-RNAオリゴ
Chol-overhang 0(2)
Chol-overhang 2base(2)
Chol-overhang 5base(2)
ミスマッチChol-RNAオリゴ
Chol―overhang 2base(11)
ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製したRNAオリゴマー(Chol―overhang 2base(1))をハイブリダイズしたGluc mRNAを用いた。
図5(A)~(D)ではいずれも最も左の列にnaked mRNAを置いたが、ミセルからmRNAが放出されると、naked mRNAと同じ位置にバンドが見られる。Chol修飾オリゴマーをハイブリダイズしていない場合、すなわち、図5(A)のPEG-PAsp(DET)-Cholを用いた場合と、図5(C)のPEG-PAsp(DET)を用いた場合には、A/P比1.5から2でミセルからの多量のmRNAの放出が観られた。一方でChol修飾オリゴマーをハイブリダイズした場合、いずれのポリマーを用いた場合も、A/P比2でもあまりmRNAの放出は観られなかった(図5(B)及び(D))。
ここでは、ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製した以下のRNAオリゴマーをハイブリダイズしたGluc mRNAを用いた。
Chol―overhang 2base(2)
Chol―overhang 2base(3)
Chol―overhang 2base(4)
Chol―overhang 2base(5)
ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製した以下のRNAオリゴマーをハイブリダイズしたGluc mRNAを用いた。
Chol―overhang 2base(2)
Chol―overhang 2base(3)
Chol―overhang 2base(4)
Chol―overhang 2base(5)
17mer(1)
Huh-7細胞(5,000cells-well)を96-wellプレートに播種し、10v/v%FBSを含むDMEM(100μL)中で24時間インキュベーションした。培地を10v/v%FBSを含む新しいものに取り替えた後、250ngのmRNAを含むPMs溶液を7.5μL加えた。24時間のインキュベーション後、DMEMの上澄みを10μL回収し、ルミノメータを用いてGlucの発光強度を測定した。
このように、Cholオリゴ修飾により、発現が上昇することがわかった。また、オリゴの個数で差は見られなかった。
ここでは実施例1-2で調製したGluc mRNA、実施例1-3で調製した以下のRNAオリゴマーをハイブリダイズしたGluc mRNA、またはそれと同じ場所に設計し3’側に2baseのoverhang配列をもつ以下の配列のオリゴマーをハイブリダイズしたGluc mRNAを用いた。
Chol―overhang 3’ 2base(1)
血清耐性試験の結果を図8(A)に、Gluc発現量の結果を図8(B)に示す。いずれの評価においても、Cholの修飾位置が3’の場合と5’の場合で大きな違いは観察されなかった。
ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製した以下のRNAオリゴマーをハイブリダイズしたGluc mRNAを用いた。
Chol―overhang 2base(2)
Chol―overhang 2base(3)
Chol―overhang 2base(4)
Chol―overhang 2base(5)
ここでは実施例1-3と同様に設計し、調製した以下のRNAオリゴ、又は後述のように調製した以下のsiRNAを用いた。「Chol―」は、RNAオリゴマーの5’末端がコレステロール修飾されていることを示す。
Chol―oligo luc(配列番号26):AAUCGAAGUACUCAGCGUA
oligo Scr(配列番号27):UCUUUGAGCACCUCCAG
Chol―oligo Scr(配列番号27):UCUUUGAGCACCUCCAG
siLuc(sense strand)(配列番号28):CUUACGCUGAGUACUUCGAdTdT
siLuc(antisense strand)(配列番号29):UCGAAGUACUCAGCGUAAGdTdT
siScramble(siScr)(sense strand)(配列番号30):UUCUCCGAACGUGUCACGUdTdT
siScr(antisense strand)(配列番号31):ACGUGACACGUUCGGAGAAdTdT
PEG-PLysは既報に従い合成した(K.Osada et al.,Biomaterials 33,325-332,(2012))(Scheme3)。合成スキームは以下のとおりである。
Chol―overhang 2base(2)
Chol―overhang 2base(3)
Chol―overhang 2base(4)
Chol―overhang 2base(5)
)を用いることで、ポリアニオンを加えた際のmRNAの放出が抑制されたほか(図11(B))、細胞に導入した際のmRNAからのタンパク質発現効率が向上した(図11(C))。一方、Chol-RNAオリゴマーを用いない場合には、A/P比1.5から2でミセルからの多量のmRNAの放出が観られた(図11(A))。従って、様々な組成のポリカチオンにおいて、Chol修飾オリゴのハイブリダイズがその安定化に有効であることが明らかとなった。
ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製した以下のRNAオリゴマーをハイブリダイズしたGluc mRNAを用いた。
Chol―overhang 2base(2)
Chol―overhang 2base(3)
Chol―overhang 2base(4)
Chol―overhang 2base(5)
Chol―overhang 2base(6)
Chol―overhang 2base(7)
Chol―overhang 2base(8)
Chol―overhang 2base(9)
Chol―overhang 2base(10)
ここでは実施例1-2で調製したGluc mRNA又は実施例1-3で調製した以下のRNAオリゴマーをハイブリダイズしたGluc mRNAを用いた。
Chol―overhang 2base(2)
Chol―overhang 2base(3)
Chol―overhang 2base(4)
Chol―overhang 2base(5)
PEG化mRNAを、以下のように作製した。RNA2次構造予測ソフトウェア(http://rtips.dna.bio.keio.ac.jp/ipknot/)にて、Gluc mRNAの2次構造を予測し、RNA鎖が2次構造を持たない部分に対してRNAオリゴマーを設計した。RNAオリゴマーは、5’末端のPEG修飾を含めて、ジーンデザイン社にて、依頼合成した。ここで、重量平均分子量12,000の直鎖PEGを用いた。そして、以下の5’末端PEG修飾RNAオリゴマーをジーンデザイン社より購入した。
配列p2(配列番号35):5’―PEG-CUCGGCCACAGCGAUGC―3’
配列p3(配列番号36):5’―PEG-UCUUUGAGCACCUCCAG―3’
配列p4(配列番号37):5’―PEG-CUCUAGAUGCAUGCUCG―3’
配列p5(配列番号38):5’―PEG-GCGGCAGCCACUUCUUG―3’
配列p6(配列番号39):5’―PEG-AUCUCAGGAAUGUCGAC―3’
配列p7(配列番号40):5’―PEG-GCAGCCAGCUUUCCGGG―3’
配列p8(配列番号41):5’―PEG-UUGAGGCAGCCAGUUGU―3’
配列p9(配列番号42):5’―PEG-UGAUCUUGUCCACCUGG―3’
配列p10(配列番号43):5’―PEG-GAUGAACUUCUUCAUCU―3’
配列p11(配列番号44):5’―PEG-GUGGGACAGGCAGAUCA―3’
配列p12(配列番号45):5’―PEG-UUGAAGUCUUCGUUGUU―3’
配列p13(配列番号46):5’―PEG-GGGCAACUUCCCGCGGU―3’
配列p14(配列番号47):5’―PEG-CUGCUCCAUGGGCUCCA―3’
配列p15(配列番号48):5’―PEG-CUUGCUGGCAAAGGUCG―3’
1箇所、5箇所、10箇所、又は15箇所にPEG修飾RNAオリゴマーをハイブリダイズしたmRNAを用いた。尚、PEGRNA修飾オリゴマー1個、5個、10個、及び15個の各実験では、実施例1-15で作製した以下のPEG修飾RNAオリゴマーを用いた。
PEG修飾RNAオリゴマー5個の実験:配列p1~p5
PEG修飾RNAオリゴマー10個の実験:配列p1~p10
PEG修飾RNAオリゴマー15個の実験:配列p1~p15
実験は、それぞれ3回行った。
ここで、図18中、「*」はオリゴ修飾していない場合と比べた場合、p<0.05という統計学的有意差があることを示す。統計処理はANOVA検定ののち、オリゴ修飾していない場合をコントロールとしたDunnett検定を行った。
1箇所、5箇所、10箇所、又は15箇所にPEG修飾RNAオリゴマーをハイブリダイズしたmRNAを用いた。尚、PEG修飾オリゴマー1個、5個、10個、及び15個の各実験では、実施例1-15で作製した以下のPEG修飾オリゴマーを用いた。
PEG修飾オリゴマー5個の実験:配列p1~p5
PEG修飾オリゴマー10個の実験:配列p1~p10
PEG修飾オリゴマー15個の実験:配列p1~p15
実験は、それぞれ3回行った。
Reverse(配列番号50):GTCAGAACACTGCACGTTGG
15箇所にPEG修飾RNAオリゴマーをハイブリダイズしたmRNAを用いた。尚、PEG修飾オリゴマー15個の実験では、実施例1-15で作製した以下のPEG修飾オリゴマーを用いた。
実験は、それぞれ3回行った。
T7-Gluc plasmidは、pCMV-Gluc control plasmid(New England BioLabs,Ipswich,MA,USA)からGlucコード配列(配列番号57及び図33)をpSP73ベクター(Promega)のHindIII,Xba1サイトに挿入することで作製した。
Gluc sense鎖(配列番号51及び図27)
Gluc antisense鎖(poly U込み)(配列番号52及び図28)
Gluc antisense鎖(poly Uなし)(配列番号53及び図29)
poly U(配列番号54及び図30)
DC2.4細胞を6well plateに1,000,000/well蒔き、24h後に培地を交換し、無血清培地Opti-MEM(商品名)(Thermo Fisher Scientific)に置換したのち、Lipofectamine(商品名) LTX(Thermo Fisher Scientific)を用いてmRNAを2.5μg/well投与した。4時間後、細胞からRNeasy mini kit(QIAGEN)にてRNAを精製し、ReverTra Ace qPCR RT Master Mix(TOYOBO)にてcomplementary DNA(cDNA)にした後、taqman gene expression assay(Applied Biosystems)を用いて、インターフェロンβの発現量を調べた。この際、actin bの発現量にて標準化した。また培地に含まれるGlucタンパク質量をRenilla Luciferase Assay System (Promega)にて定量した。
mRNA:poly Uは実施例2-2と同様に作製した。Gluc mRNA 3μgを含む10μLの10 mM Hepes溶液をC57BL6Nマウスの鼠径リンパ節に投与した。4時間後、鼠径リンパ節を回収し、Passive lysis buffer(Promega)にて溶解し、Luc発現量をRenilla Luciferase Assay System(Promega)にて定量した。また、RNAをRNeasy mini kit(QIAGEN)にて抽出し、ReverTra Ace qPCR RT Master Mix(TOYOBO)にてcomplementary DNA (cDNA)にした後、taqman gene expression assay(Thermo Fisher Scientific)を用いて、インターフェロンβ及びインターロイキン6の発現量を調べた。この際、actin bの発現量にて標準化した。
T7-OVA poly A120 plasmidは、Genscript社にてコドン最適化を行ったOVAコード配列(配列番号58及び図34)をpSP73ベクター(Promega)のXhoI、EcoR1サイトに挿入することで作成した。OVA sense鎖は、T7-OVA poly A120 plasmidをBsmBIで切断し、mMESSAGE mMACHINE T7 Ultra Kit(Thermo Fisher Scientific)にてT7プロモーターより転写することで作製した。poly UはT7-Gluc poly A120 plasmidをEcoRIで切断し、MEGAscript(登録商標) SP6 Transcription Kit(Thermo Fisher Scientific)にてSp6プロモーターより転写することで作製した。
ここで、poly Uは、poly A全体の配列に相補的な配列(120塩基)と、その下流に、mRNAの3’UTRの一部(すなわち、3’UTRの約83%の塩基長の配列)に相補的な配列(5塩基)を含む。尚、ここで用いたpoly Uは、SP6プロモーター内の配列、及び、クローニングに用いた制限酵素配列を他の配列(17塩基)としてさらに含む。すなわち、ここで用いたpoly Uは、142塩基長の配列を有する。また、5’末端にトリリン酸構造を有する。
OVA sense鎖(配列番号55及び図31)
poly U(配列番号56及び図32)
AやUの数に関しては、実施例2-1の場合と同様であり、T7プロモーターから転写したmRNAは119塩基のAを、Sp6プロモーターから転写したRNAは120塩基のUをそれぞれ有する。しかし、DNA増幅や、mRNA調製の段階でその数は増減しうる。
実施例2-4と同様の方法でOVA mRNAをC57BL6Nマウスに投与し、7日後に血液を採取した(図26(A))。血清中の抗OVA IgGをMouse Anti-OVA IgG Antibody Assay Kit(コンドレックス社)にて定量した。
実施例2-2と同様の方法で、樹状細胞(D.C.2.4細胞)におけるmRNAからのタンパク質発現量(すなわちルシフェラーゼ発現量)を定量した。
ただし、D.C.2.4細胞を96well plateに40,000/well蒔いて実験を行った。また、RNAオリゴマーとして、以下の3つを用いた。
poly U(3’UTRと相補的な配列の鎖長:5塩基)(配列番号56、図36(B))
poly U(3’UTRと相補的な配列の鎖長:19塩基)(配列番号54、図36(B))
poly U(3’UTRと相補的な配列の鎖長:50塩基)(配列番号59、図36(B))
「poly U(3’UTRと相補的な配列の鎖長:19塩基)(配列番号54)」T7-Gluc poly A120 plasmidをSmaIで切断し、MEGAscript(登録商標) SP6 Transcription Kit(Thermo Fisher Scientific)にてSp6プロモーターより転写することで作製した(図36(A))。
尚、「poly U(3’UTRと相補的な配列の鎖長:5塩基)(配列番号56)」は、mRNAの3’UTRの一部(すなわち、3’UTR(52塩基長)の約10%の塩基長の配列)に相補的な配列(5塩基)を含む。
また、poly U(3’UTRと相補的な配列の鎖長:19塩基)は、mRNAの3’UTRの一部(すなわち、3’UTR(52塩基長)の約36%の塩基長の配列)に相補的な配列(19塩基)を含む。
ここで、poly Uは、poly A全体の配列に相補的な配列(120塩基)と、その下流に、mRNAの3’UTRの一部(すなわち、3’UTR(52塩基長)の約96%の塩基長の配列)に相補的な配列(50塩基)を含む。尚、ここで用いたpoly Uは、SP6プロモーター内の配列、及び、クローニングに用いた制限酵素配列を他の配列(17塩基)としてさらに含む。すなわち、ここで用いたpoly Uは、187塩基長の配列を有する。また、5’末端にトリリン酸構造を有する。
合成RNAオリゴマーを以下のように作製した。先ず、Gluc mRNAに相補的な第1の配列については、RNA2次構造予測ソフトウェア(http://rtips.dna.bio.keio.ac.jp/ipknot/)にて、Gluc mRNAの2次構造を予測し、RNA鎖が2次構造を持たない部分に対してRNAオリゴマーを設計した。overhang配列については、可能な限りmRNA鎖とハイブリダイズしないようAまたはUを用いて設計した。5’ppp-RNAオリゴマーと相補的な第2の配列については、先ず、5’ppp-RNAオリゴマーの配列を設計し、その配列に相補的な第2の配列を得た。5’ppp-RNAオリゴマーではGUの繰り返し配列を用いたが、これは、ATPを含まない系でin vitro転写をすることにより、相補鎖の副産物の生成が抑制されるほか、GU繰り返し配列はそのRNA自体で2次構造を形成しないことが特徴である。この5’ppp-RNAオリゴマーに相補的な配列として第2の配列を得たが、この際、5’ppp-RNAオリゴマーのトリリン酸化された5’末端が平滑になるよう配列設計を行っている。。
合成RNAオリゴマーは北海道システムサイエンスより購入した。
合成RNAオリゴマー配列2(配列番号61):ACUCUUUGUCGCCUUCGAUCACACACACACACACACACACACC
合成RNAオリゴマー配列3(配列番号62):GCGGCAGCCACUUCUUGUACACACACACACACACACACACACC
DNAオリゴマー(配列番号64):AAACGGGCCCACACACACACACACACACACA
また、実施例3-3では、「mRNA:pU」として、実施例2-1で調製した「mRNA:polyU」を用いた。
DC2.4細胞を12 well plateに400,000/well蒔き、24h後に培地を交換し、無血清培地Opti-MEM(商品名)(Thermo Fisher Scientific)に置換したのち、Lipofectamine(商品名) LTX(Thermo Fisher Scientific)を用いてmRNAを2.5μg/well投与した。4時間後、細胞からRNeasy mini kit(QIAGEN)にてRNAを精製し、ReverTra Ace qPCR RT Master Mix(TOYOBO)にてcomplementary DNA(cDNA)にした後、taqman gene expression assay(Applied Biosystems)を用いて、インターフェロンβおよびインターロイキン6の発現量を調べた。この際、actin bの発現量にて標準化した。
DC2.4細胞を96 well plateに40,000/well蒔き、24h後に培地を交換し、無血清培地Opti-MEM(商品名)(Thermo Fisher Scientific)に置換したのち、Lipofectamine(商品名) LTX(Thermo Fisher Scientific)を用いてmRNAを0.25μg/well投与した。4時間後Glucタンパク質量をRenilla Luciferase Assay System (Promega)にて定量した。
ここで図38~40のP値は、統計処理としてANOVA検定ののち、Tukey検定を行った際の統計学的有意差を示す。
配列番号28~31:合成DNA/RNA
配列番号32:合成DNA
配列番号33:合成RNA
配列番号34~48:合成RNA
配列番号49及び50:合成DNA
配列番号57及び58:合成DNA
配列番号59:合成RNA
配列番号63~65:合成DNA
配列番号66~68:合成RNA
Claims (30)
- mRNAと、mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを含む二本鎖RNAを含む、機能化mRNA。
- 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを内包した前記mRNAの輸送担体であって、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、輸送担体。 - 前記RNA配列が15~23塩基の配列からなる、請求項2に記載の輸送担体。
- 前記RNA配列が17塩基の配列からなる、請求項3に記載の輸送担体。
- 前記化学修飾は、1~5塩基のオーバーハング配列を介してRNAオリゴマーの配列の5’末端又は3’末端になされたものである、請求項2~4のいずれか1項に記載の輸送担体。
- 前記オーバーハング配列が2塩基の配列である、請求項5に記載の輸送担体。
- 前記化学修飾が疎水性基による修飾である、請求項2~6のいずれか1項に記載の輸送担体。
- 前記疎水性基による修飾がコレステロール修飾である、請求項7に記載の輸送担体。
- 前記化学修飾がポリエレングリコール修飾である、請求項2~6のいずれか1項に記載の輸送担体。
- 前記輸送担体が、高分子ミセル又は脂質性mRNAキャリアである、請求項1~9のいずれか1項に記載の輸送担体。
- 請求項1~10のいずれか1項に記載の輸送担体を含有する、医薬組成物。
- 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを輸送担体に内包させることを含み、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されている、輸送担体の安定化方法。 - 目的遺伝子をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つのRNAオリゴマーとを含む二本鎖RNAであって、
RNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなるRNA配列、又は
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズするRNA配列
を含み、かつ化学修飾されていない又は化学修飾されている、二本鎖RNA。 - 抗原をコードするmRNAと、当該mRNAの少なくともpoly A配列にハイブリダイズした少なくとも1つのRNAオリゴマーからなる二本鎖RNAを含み、前記少なくとも1つのRNAオリゴマーは化学修飾されていない又は化学修飾されている、mRNAワクチン。
- RNAオリゴマーは、10~500塩基配列からなる、請求項14に記載のmRNAワクチン。
- RNAオリゴマーは、5’末端にトリリン酸構造を有する、請求項14又は15に記載のmRNAワクチン。
- 二本鎖RNAは、mRNAの少なくともpoly A配列に1つのRNAオリゴマーがハイブリダイズしたものである、請求項14~16のいずれか1項に記載のmRNAワクチン。
- 二本鎖RNAがネイキッドの形態である、請求項14~17のいずれか1項に記載のmRNAワクチン。
- アジュバントと共に用いない、請求項14~18のいずれか1項に記載のmRNAワクチン。
- 疾患の予防又は治療を必要とする対象において当該疾患の予防又は治療に用いるための、請求項14~19のいずれか1項に記載のmRNAワクチン。
- 抗原をコードするmRNAと、当該mRNAにハイブリダイズした少なくとも1つの第1のRNAオリゴマーと、当該第1のRNAオリゴマーにハイブリダイズした第2のRNAオリゴマーからなる二本鎖RNAを含み、
第1のRNAオリゴマーは、
(a)mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(b)mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列を、5’末端よりこの順に含むRNA配列、
(c)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列からなる第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列からなる第1のRNA配列を、5’末端よりこの順に含むRNA配列、又は
(d)第2のRNAオリゴマーの配列に相補的な10~200塩基の配列と90%以上の同一性を有し、かつ第2のRNAオリゴマーにハイブリダイズする第2のRNA配列と、mRNAの配列に相補的な12~40塩基の配列と90%以上の同一性を有し、かつmRNAにハイブリダイズする第1のRNA配列と、5’末端よりこの順に含むRNA配列
を含む、mRNAワクチン。 - 第1のRNAオリゴマーは、22~240塩基の配列からなる、請求項21に記載のmRNAワクチン。
- 1つのmRNAにハイブリダイズさせる第1のRNAオリゴマーの数が、1~50個である、請求項21または22に記載のmRNAワクチン。
- 第1のRNAオリゴマーは、前記(a)のRNA配列又は前記(b)のRNA配列を含み、第2のRNAオリゴマーは、5’末端にトリリン酸構造を有する、請求項21~23のいずれか1項に記載のmRNAワクチン。
- 第1のRNAオリゴマーは、前記(c)のRNA配列又は前記(d)のRNA配列を含み、第1のRNAオリゴマーは、5’末端にトリリン酸構造を有する、請求項21~23のいずれか1項に記載のmRNAワクチン。
- 第2のRNAオリゴマーが第1のRNAオリゴマーにハイブリダイズしている側の二本鎖RNAの末端が、平滑末端である、請求項21~25のいずれか1項に記載のmRNAワクチン。
- 第2のRNAオリゴマーは10~200塩基の配列を含む、請求項21~26のいずれか1項に記載のmRNAワクチン。
- 二本鎖RNAがネイキッドの形態である、請求項21~27のいずれか1項に記載のmRNAワクチン。
- アジュバントと共に用いない、請求項21~28のいずれか1項に記載のmRNAワクチン。
- 疾患の予防又は治療を必要とする対象において当該疾患の予防又は治療に用いるための、請求項21~29のいずれか1項に記載のmRNAワクチン。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310810591.8A CN116949050A (zh) | 2016-12-27 | 2017-12-27 | mRNA的功能化方法 |
JP2018559579A JP6792847B2 (ja) | 2016-12-27 | 2017-12-27 | mRNAの機能化方法 |
KR1020197022206A KR102259447B1 (ko) | 2016-12-27 | 2017-12-27 | mRNA 의 기능화 방법 |
EP17889018.2A EP3564375A4 (en) | 2016-12-27 | 2017-12-27 | ARNM FUNCTIONALIZATION PROCESS |
CN201780080567.6A CN110168090B (zh) | 2016-12-27 | 2017-12-27 | mRNA的功能化方法 |
US16/473,535 US11364259B2 (en) | 2016-12-27 | 2017-12-27 | MRNA functionalization method |
US17/745,314 US20220296632A1 (en) | 2016-12-27 | 2022-05-16 | Mrna functionalization method |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-252488 | 2016-12-27 | ||
JP2016252487 | 2016-12-27 | ||
JP2016-252487 | 2016-12-27 | ||
JP2016252488 | 2016-12-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/473,535 A-371-Of-International US11364259B2 (en) | 2016-12-27 | 2017-12-27 | MRNA functionalization method |
US17/745,314 Division US20220296632A1 (en) | 2016-12-27 | 2022-05-16 | Mrna functionalization method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018124181A1 true WO2018124181A1 (ja) | 2018-07-05 |
Family
ID=62708134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/046906 WO2018124181A1 (ja) | 2016-12-27 | 2017-12-27 | mRNAの機能化方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11364259B2 (ja) |
EP (1) | EP3564375A4 (ja) |
JP (2) | JP6792847B2 (ja) |
KR (1) | KR102259447B1 (ja) |
CN (2) | CN110168090B (ja) |
WO (1) | WO2018124181A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019093423A1 (ja) * | 2017-11-09 | 2019-05-16 | 国立大学法人東京大学 | mRNAの安定化方法 |
WO2022004765A1 (ja) * | 2020-06-30 | 2022-01-06 | 公益財団法人川崎市産業振興財団 | ゲノム編集用組成物 |
WO2023145755A1 (ja) | 2022-01-25 | 2023-08-03 | 公益財団法人川崎市産業振興財団 | 経皮投与用のrnaを含む組成物および当該組成物の投与方法 |
WO2024128201A1 (ja) * | 2022-12-12 | 2024-06-20 | 京都府公立大学法人 | mRNAワクチン |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202112922WA (en) | 2019-05-22 | 2021-12-30 | Massachusetts Inst Technology | Circular rna compositions and methods |
EP3920976B1 (en) | 2019-12-04 | 2023-07-19 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
JP2023527309A (ja) * | 2020-05-19 | 2023-06-28 | オルナ セラピューティクス インコーポレイテッド | 環状rna組成物及び方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010540500A (ja) * | 2007-09-28 | 2010-12-24 | ビオマイ アクチエンゲゼルシャフト | Rnaワクチン |
JP2012502074A (ja) | 2008-09-30 | 2012-01-26 | キュアバック ゲーエムベーハー | 哺乳動物において免疫を賦活する応答を提供または増強するための複合化された(m)RNAと裸のmRNAとを含んでいる組成物、およびその使用 |
WO2015121924A1 (ja) | 2014-02-12 | 2015-08-20 | 一般社団法人医療産業イノベーション機構 | mRNA送達用組成物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
NZ528644A (en) | 2001-03-08 | 2005-05-27 | Boehringer Ingelheim Ca Ltd | A method for identifying a potential inhibitor of the binding between a HCV NS5B RNA-dependent RNA polymerase and an appropriate primer-template |
US7803781B2 (en) * | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US8796436B2 (en) * | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
EP1699924B1 (en) * | 2003-12-03 | 2019-09-04 | Ocunexus Therapeutics, Inc. | Inhibitory compounds targeted to connexin 43 and methods of use thereof in the treatment of corneal eye trauma |
EP1910528A2 (de) | 2005-07-25 | 2008-04-16 | Technische Universität Dresden | Rna-abhängige rna-polymerase, verfahren und kits zur amplifikation und / oder markierung von rna |
US8106173B2 (en) * | 2006-04-07 | 2012-01-31 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 |
WO2009154804A2 (en) * | 2008-06-20 | 2009-12-23 | Thomas Jefferson University | Twin fluorophore peptide nucleic acid hybridization probes |
EP2280081A1 (en) | 2009-07-31 | 2011-02-02 | Qiagen GmbH | Method of normalized quantification of RNA |
DK2591792T3 (en) * | 2010-07-09 | 2017-04-03 | Univ Tokyo | COMPOSITION FOR NUCLEIC ACID RELEASE, CARRIER COMPOSITION, PHARMACEUTICAL COMPOSITION WITH COMPOSITION FOR NUCLEIC ACID RELEASE OR CARRIER COMPOSITION AND PROCEDURE FOR NUCLEAR PROCESS |
WO2012109476A2 (en) * | 2011-02-09 | 2012-08-16 | The University Of Rochester | Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements |
EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
WO2015051045A2 (en) * | 2013-10-04 | 2015-04-09 | Novartis Ag | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE |
CN110302394A (zh) * | 2013-11-22 | 2019-10-08 | 国立大学法人东京大学 | 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法 |
-
2017
- 2017-12-27 KR KR1020197022206A patent/KR102259447B1/ko active IP Right Grant
- 2017-12-27 WO PCT/JP2017/046906 patent/WO2018124181A1/ja unknown
- 2017-12-27 US US16/473,535 patent/US11364259B2/en active Active
- 2017-12-27 CN CN201780080567.6A patent/CN110168090B/zh active Active
- 2017-12-27 JP JP2018559579A patent/JP6792847B2/ja active Active
- 2017-12-27 CN CN202310810591.8A patent/CN116949050A/zh active Pending
- 2017-12-27 EP EP17889018.2A patent/EP3564375A4/en active Pending
-
2020
- 2020-10-28 JP JP2020180549A patent/JP7264378B2/ja active Active
-
2022
- 2022-05-16 US US17/745,314 patent/US20220296632A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010540500A (ja) * | 2007-09-28 | 2010-12-24 | ビオマイ アクチエンゲゼルシャフト | Rnaワクチン |
JP2012502074A (ja) | 2008-09-30 | 2012-01-26 | キュアバック ゲーエムベーハー | 哺乳動物において免疫を賦活する応答を提供または増強するための複合化された(m)RNAと裸のmRNAとを含んでいる組成物、およびその使用 |
WO2015121924A1 (ja) | 2014-02-12 | 2015-08-20 | 一般社団法人医療産業イノベーション機構 | mRNA送達用組成物 |
Non-Patent Citations (12)
Title |
---|
ALTZSHUL S.F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 |
BLOOD, vol. 108, no. 13, 2006, pages 4009 - 17 |
K. OSADA ET AL., BIOMATERIALS, vol. 33, 2012, pages 325 - 332 |
KARL-JOSEF KALLEN ET AL., HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 9, no. 10, 2013, pages 2263 - 2276 |
M. OISHI ET AL., CHEM BIO CHEM, vol. 6, no. 4, 2005, pages 718 - 725 |
MEIS, J. E.CHEN, F., EPICENTRE FORUM, vol. 9, no. 1, 2002, pages 10 |
MIYATA, K. ET AL., BIOMATERIALS, vol. 31, 2010, pages 4764 - 4770 |
OBA, M. ET AL., BIOMATERIALS, vol. 32, 2011, pages 3106 - 3114 |
OSAWA, S. ET AL., BIOMACROMOLECULES, vol. 17, 2016, pages 354 - 361 |
S. L. BEAUCAGE ET AL., TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859 - 1862 |
UCHIDA, S. ET AL., BIOMATERIALS, vol. 82, 2016, pages 221 - 228 |
UCHIDA, S. ET AL.: "Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination", BIOMATERIALS, vol. 150, 27 September 2017 (2017-09-27), pages 162 - 170, XP085246319, ISSN: 0142-9612 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019093423A1 (ja) * | 2017-11-09 | 2019-05-16 | 国立大学法人東京大学 | mRNAの安定化方法 |
WO2022004765A1 (ja) * | 2020-06-30 | 2022-01-06 | 公益財団法人川崎市産業振興財団 | ゲノム編集用組成物 |
WO2023145755A1 (ja) | 2022-01-25 | 2023-08-03 | 公益財団法人川崎市産業振興財団 | 経皮投与用のrnaを含む組成物および当該組成物の投与方法 |
WO2024128201A1 (ja) * | 2022-12-12 | 2024-06-20 | 京都府公立大学法人 | mRNAワクチン |
Also Published As
Publication number | Publication date |
---|---|
US11364259B2 (en) | 2022-06-21 |
US20190328769A1 (en) | 2019-10-31 |
EP3564375A4 (en) | 2020-12-16 |
CN116949050A (zh) | 2023-10-27 |
CN110168090A (zh) | 2019-08-23 |
KR20190102041A (ko) | 2019-09-02 |
US20220296632A1 (en) | 2022-09-22 |
KR102259447B1 (ko) | 2021-06-02 |
CN110168090B (zh) | 2023-07-18 |
JPWO2018124181A1 (ja) | 2019-10-31 |
JP6792847B2 (ja) | 2020-12-02 |
JP7264378B2 (ja) | 2023-04-25 |
EP3564375A1 (en) | 2019-11-06 |
JP2021035377A (ja) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7264378B2 (ja) | mRNAの機能化方法 | |
KR102285326B1 (ko) | Rna를 세포에 도입하기 위한 조성물 | |
KR102142180B1 (ko) | 세포에 핵산을 도입하기 위한 조성물 | |
KR20210021943A (ko) | 미립자 제형용 동결 방지제 | |
AU2013242403B2 (en) | Artificial nucleic acid molecules | |
JPH09508100A (ja) | 核酸を含む組成物、調製および使用 | |
US20230332154A1 (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same | |
US20240122866A1 (en) | Cationic polymer-formulated nanoparticles and methods of use | |
JP6960641B2 (ja) | mRNAの安定化方法 | |
Zhao et al. | Recent Progress in Biomedical Applications of Chitosan Derivatives as Gene Carrier | |
WO2024128201A1 (ja) | mRNAワクチン | |
JP7554850B2 (ja) | アンフィレギュリン特異的な二本鎖オリゴヌクレオチド構造体を含む肥満関連疾患の予防及び治療用組成物 | |
WO2022004765A1 (ja) | ゲノム編集用組成物 | |
Bogadi et al. | Nucleic Acid-Based Micellar Therapy for the Treatment of Different Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17889018 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018559579 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197022206 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017889018 Country of ref document: EP Effective date: 20190729 |